Paper Publish Year,DOI,Category (Protein Mimetic),Mimic of which Protein,Name of the Protein Mimetic,Functions,Activity
2007,https://doi.org/10.2174/156802607779318325,cyclic peptide,extracellular matrix proteins that contain the Arg-Gly-Asp (RGD) sequence,c(RGDfV),Integrin antagonist : blocks integrin αVβ3 receptor binding,Inhibits angiogenesis : prevents tumor-induced blood vessel formation
2007,https://doi.org/10.2174/156802607779318325,cyclic peptide,Disintegrins,ACDCRGDCFCG,acts as an integrin antagonist by blocking the binding of natural ligands to integrin receptors like αVβ3 and αIIbβ3.,"It inhibits cell adhesion and migration, disrupting processes such as angiogenesis and tumor progression."
2007,https://doi.org/10.2174/156802607779318325,non peptide,type-II′ β-turn,"2-Amino-3-oxo-11b(R)-hexahydroindolizino[8,7-b]indole-5(S)-carboxylate",Mimics the structure and function of natural peptides or proteins to modulate biological interactions.,"Interacts with biological targets to influence processes like protein-protein interactions, potentially impacting cellular functions or signaling pathways."
2007,https://doi.org/10.2174/156802607779318325,β-turn mimetic,"Bcl-2 family proteins (e.g., Bcl-xL) and p53",γ-Amino acid derivatives,"Mimic β-turn conformations, influencing peptide conformations and interactions","Stabilize or mimic β-turns, affecting biological activity and binding interactions"
2007,https://doi.org/10.2174/156802607779318325,peptide,clic pentapeptide,diketopiperazine (DKP),Mimics peptide structures to support functional side chains.,Acts as an antagonist (specifically for CXCR4).
2007,https://doi.org/10.2174/156802607779318325,cyclic peptide,αIIbβ3 integrin receptor,Cyclic RGD-containing disulfide derivative,Antagonist of the αIIbβ3 integrin receptor,Highly active antagonist with extended conformation at Gly residue
2007,https://doi.org/10.1039/b710425a,Synthetic backbone scaffold,α-helices peptides,Terphenyl scaffold,Designed to project sidechain functionality similar to that found in α-helices.,Used as inhibitors of protein–protein interactions
2007,https://doi.org/10.1039/b710425a,Peptide mimetic,human parathyroid hormone (hPTH),Truncated mimetic of human parathyroid hormone (hPTH),Stabilized by lactam bridges to enhance its biological activity,elivers therapeutic osteogenic agents with high potency.
2007,https://doi.org/10.1039/b710425a,Peptide mimetic,Respiratory syncytial virus (RSV) protein,Cyclic pentapeptide scaffold,Mimics the α-turns of the RSV protein.,"Inhibits fusion of viral and cell membranes, preventing viral entry into cells."
2007,https://doi.org/10.1039/b710425a,Peptide mimetic,α-helices peptides,Hydrazone-linked peptides,To stabilize α-helical structures by replacing the N-terminal i and i + 4 hydrogen bond with a covalent link,Forms well-defined short α-helices with minimal perturbations to molecular recognition surfaces.
2007,https://doi.org/10.1039/b710425a,Synthetic scaffold,Marine toxin-related α-helical structures,Trans-fused tetracyclic ethers,To create a receptor for sequence-selective binding of spaced aspartate pairs on the surface of α-helical peptides.,Intended to disrupt protein–protein interactions and bind larger areas in a cell-permeable manner
2007,https://doi.org/10.1039/b710425a,Peptide mimetic,α-helices peptides,Carbon–Carbon Linked Peptides,Introduces a carbon–carbon bond to stabilize the helical structure.,"Results in well-defined short α-helices from sequences that do not spontaneously form helices, with minimal perturbations to their molecular recognition surfaces"
2007,https://doi.org/10.1039/b710425a,Peptide mimetic,TTTT(Type I antifreeze proteins (AFPs)),"15-residue peptide with a single Thr repeat and i, i + 4 lactam bridge",Stabilizes a pyramidal plane on the surface of growing ice crystals.,"Shows potential antifreeze activity, but not as effective as TTTT."
2007,https://doi.org/10.1039/b710425a,Peptide mimetic,TTTT(Type I antifreeze proteins (AFPs)),Ala-rich peptides with spaced Lys residues,Exhibits antifreeze activity.,Weaker antifreeze activity compared to TTTT.
2007,https://doi.org/10.1152/ajpcell.00097.2007,Connexin mimetic peptide,Cx43,43Gap26,Inhibits gap junction channel formation,Attenuates junctional conductance over time
2007,https://doi.org/10.1152/ajpcell.00097.2007,Connexin mimetic peptide,Cx43,43Gap27,Inhibits gap junction channel formation,No acute effect but moderate long-term attenuation of membrane conductance
2007,https://doi.org/10.1152/ajpcell.00097.2007,Connexin mimetic peptide,Cx32,32Gap24,Attenuates nonjunctional membrane conductance,No acute effect on membrane conductance
2007,https://doi.org/10.1152/ajpcell.00097.2007,Connexin chimera,Cx32 (with sequence from Cx43),Cx32E143,Forms both gap junction channels and nonjunctional conductance,Provides a model to study Cx32 channels
2007,https://doi.org/10.1152/ajpcell.00097.2007,Pannexin mimetic peptide,Pannexin-1,PanxE1b,Mimics extracellular loop sequences of pannexin1,Inhibits pannexin currents by more than 10%.
2007,https://doi.org/10.1152/ajpcell.00097.2007,Pannexin mimetic peptide,Pannexin-1,10Panx1,Blocks pannexin-1 channel activity,Inhibits pannexin-1 channels; used to study ATP release and intercellular calcium wave propagation
2007,https://doi.org/10.1002/anie.200700657,α-helix mimetic,Bak BH3 domain,"2,3’,3’’-trisubstituted terphenyls","Mimics i, i+4, and i+7 residues of an α-helix","Inhibits protein–helix interactions, such as Bcl-xL/Bak and MDM2/p53"
2007,https://doi.org/10.1002/anie.200700657,α-helix mimetic,Coactivator LXXLL motif,Biaryl scaffold (with ortho substituent),"Mimics i, i+3, and i+4 residues of an α-helix","Inhibits helix–protein interactions, specifically mimicking LXXLL motif"
2007,https://doi.org/10.4161/auto.4237,BH3 mimetic,BH3,ABT737,"Competitively inhibits the interaction between Beclin 1 and Bcl-2/Bcl-XL, which stimulates autophagy","ABT737 disrupts the inhibitory complex between Beclin 1 and Bcl-2/Bcl-XL, thus promoting autophagy by liberating Beclin 1 from its inhibition"
2007,https://doi.org/10.1016/j.beem.2007.09.003,NA,GLP-1,"exendin-4(1–39), exenatide, or AC-2993",a DPP-4-resistant GLP-1 receptor agonist isolated from the saliva of the Gila monster (Heloderma suspectum),exendin-4 replicates all of the known biological actions of GLP-1
2007,https://doi.org/10.1016/j.beem.2007.09.003,NA,GLP-1,exenatide LAR,clinical trails for type-2 diabetes.,Once-weekly administration (0.8 or 2 mg) of exenatide LAR to type-2 diabetic patients for 15 weeks lowered HbA1c (1.4–1.7%) and reduced body weight (up to 3.8 kg).
2007,https://doi.org/10.1016/j.beem.2007.09.003,Non-peptide incretin mimetics,incretin,Boc5,stimulated glucose-dependent insulin secretion and lowered food intake in mice.,The effects of Boc5 were countered by co-administration of exendin(9–39). injection of Boc5 to db/db mice over a 6-week period significantly lowered HbA1c values
2007,https://doi.org/10.1016/j.beem.2007.09.003,peptide,GLP-1,PEG-DAPD,improved plasma half-life in vivo,"improves glucose tolerance and reduces blood glucose following a glucagon challenge.PEGylation appears to eliminate the inhibitory effect of DADP on gastrointestinal motility, and it is hoped that this will prevent the more significant gastrointestinal side-effects such as nausea and vomiting."
2007,https://doi.org/10.1158/0008-5472.CAN-07-5173,Smac mimetic compound,Smac,LBW242,"argets inhibitor of apoptosis proteins (IAPs) such as XIAP and cIAP1, leading to the induction of apoptosis in cancer cells","induces apoptosis in cancer cells by activating caspase-8, increasing TNFa expression, and overcoming drug resistance."
2007,https://doi.org/10.1128/aac.00208-07,peptide,melittin and lactoferricin.,meta-phenylene ethynylene,use as therapeutic anti-infectives in the treatment of oral infectious diseases,"rapid activity against several prolific oral pathogens and efficacy in treating oral biofilms,  activity against other biofilm sources is
warranted, as its efficacy may extend to other commercial applications"
2007,https://doi.org/10.1099/jmm.0.46920-0,mimotopes,phosphoinositides,Mannosylated lipoarabinomannan (ManLAM),"sera of TB patients, as well as the sera of mice experimentally infected with M. tuberculosis, contained significant levels of antibodies that recognized ManLAM.",it bound the anti-ManLAM CS40 mAb and competed with ManLAM for antibody binding.
2007,https://doi.org/10.1002/pbc.21433,small molecule,BH3,ABT-263,limited single agent in vivo activity against the PPTP’s solid tumor panels but showed significant activity against xenografts in the ALL panel,"inhibits the antiapoptotic proteins Bcl-2, Bcl-xL and Bcl-w, demonstrated in vitro activity against a range of cell lines, with the
ALL cell lines showing the greatest sensitivity"
2007,https://doi.org/10.1002/pbc.21433,small molecule,BH3,ABT-737,"exhibits single-agent preclinical activity against lymphoma, small-cell lung carcinoma, and chronic lymphocytic leukemia and displays synergistic cytotoxicity with chemotherapeutics and radiation.",Bcl-2 inhibitor
2007,https://doi.org/10.1371/journal.pmed.0040316,small molecule,BH3,ABT-737,"its addition significantly enhances killing of NSCLC cells by
the EGFR tyrosine kinase inhibitor gefitinib",EGFR tyrosine kinase inhibitor gefitinib.
2008,https://doi.org/10.1002/bip.20979,Quaternary Protein Mimetic,gp41,3α -N36,Mimics the fusogenic state of HIV-1 gp41,"Elicits neutralizing antibodies against HIV-1, inhibits viral infectivity"
2008,https://doi.org/10.1002/bip.20979,Peptide mimetic,Amyloid β-peptide (Aβ),D-[chGly-Tyr-chGly-chGly-mLeu]-NH2,Acts as an indicator for existing mature Aβ fibrils and may be used to screen for peptide-based compounds capable of binding to Aβ fibrils,Binds to Aβ fibrils and initiates fibrillization
2008,https://doi.org/10.1002/bip.20979,Peptide mimetic,Amyloid β-peptide (Aβ),KLVFF,Reduces the toxicity of Aβ to neuronal cells by coassembling with mature Aβ fibrils and soluble oligomers,Binds to Aβ fibrils
2008,https://doi.org/10.1002/bip.20979,Peptide mimetic,Amyloid β-peptide (Aβ),LVFFA,Reduces the toxicity of Aβ to neuronal cells by coassembling with mature Aβ fibrils and soluble oligomers,Binds to Aβ fibrils
2008,https://doi.org/10.1002/bip.20979,Peptide mimetic,Amyloid β-peptide (Aβ),AP13Q,recognizing Aβ and preventing its oligomerization,Binds to Aβ fibrils
2008,https://doi.org/10.1002/bip.20979,Peptide mimetic,Amyloid β-peptide (Aβ),P13H,Reduces the toxicity of Aβ to neuronal cells,Inhibits Aβ oligomerization
2008,https://doi.org/10.1016/j.drudis.2008.07.008,protein epitope mimetic,Protegrin I,IB367 (Iseganan),in clinical trials for the treat- ment of oral mucositis,antimicrobial activity and a considerably reduced hemolytic activ- ity on red blood cells
2008,https://doi.org/10.1016/j.drudis.2008.07.008,b-hairpin loops,antibody Fab fragments,Z-domain of Staphylococcus aureus protein A,Designed to mimic the structural conformation of the L3 canonical loop in antibodies,structural mimetic exhibited stable hairpin conformation
2008,https://doi.org/10.1016/j.drudis.2008.07.008,peptide,erythropoietin (EPO),Z-domain of Staphylococcus aureus protein A,activates EPO receptor,binds to EPO receptor
2008,https://doi.org/10.1016/j.drudis.2008.07.008,b-hairpin peptide mimetics,p53,Z-domain of Staphylococcus aureus protein A,Mimics the a-helical epitope of p53,binds to HDM2 with KD of 25 nM
2008,https://doi.org/10.1016/j.cbpa.2008.09.023,Receptor mimetic,G-protein coupled receptor CRF1,Z-domain of Staphylococcus aureus protein A,"The mimetic presents the N-terminus and three extracellular loops of CRF1, demonstrating specific recognition of the ligand",Recognizes and binds to the CRF1 ligand urocortin
2008,https://doi.org/10.1016/j.cbpa.2008.09.023,binding site mimetic,gp120,Synthetic CD4-binding site mimetic,Designed to mimic the CD4-binding site of gp120,"Antibodies raised against this mimetic recognize the gp120, compete with the broadly neutralizing antibody mAb b12, whose epitope overlaps the CD4-binding site, for binding to gp120"
2008,https://doi.org/10.1042/BST0361414,proteomimetic inhibitors,Bak/Bim BH3 Domains,"Trisubstituted 3,2,2-terphenyl derivatives",Mimics α-helical structure to disrupt protein–protein interactions,"central aryl ring adopts a staggered conformation, effectively mimicking the position and projection of i, i + 3 or i + 4 and i + 7 residues on one face of the helix"
2008,https://doi.org/10.1042/BST0361414,proteomimetic inhibitors,smMLCK (smooth muscle myosin light-chain kinase),The terphenyl scaffold,Disrupts protein–protein interactions,binds to calmodulin using an α-helical domain
2008,https://doi.org/10.2174/187152708783885174,Peptidomimetic,pharmacophores of mAb 5C3 and NGF peptide analogues,D3,Neuroprotective agent,"proteolytically stable agonist of the TrkA receptor, can activate a tyrosine kinase neurotrophin receptor that normally binds a relatively large protein ligand"
2008,https://doi.org/10.2174/187152708783885174,Peptidomimetic,pharmacophores of mAb 5C3 and NGF peptide analogues,C59,"C59 (Wnt-C59) is a small-molecule inhibitor of the Wnt signaling pathway. It functions by targeting Porcupine (PORCN), a membrane-bound O-acyltransferase essential for the palmitoylation and secretion of Wnt proteins, thereby preventing both canonical and non-canonical Wnt-mediated signaling.",Lacked neurotrophic effects
2008,https://doi.org/10.2174/187152708783885174,Cyclic peptide,N-cadherin,N-Ac-CHAVDINGHAVDICNH2 (SW4),Promotes survival of primary CNS neurons,"It functions by binding to and clustering N-cadherin in neurons, activating an N-cadherin/FGF signaling cascade, which is neuroprotective."
2008,https://doi.org/10.2174/187152708783885174,NCAM mimetic peptide,NCAM (Neural Cell Adhesion Molecule),C3 (C3d),Induces neurite outgrowth and promotes survival of neurons,"Binds to NCAM IgI module, mimics NCAM homophilic binding, promotes CNS neuron survival, and neurite outgrowth"
2008,https://doi.org/10.1158/1535-7163.MCT-08-0285,Small molecule mimetic,BH3,ABT-737,restores sensitivity of Bcl-2-overexpressing cells but not Mcl-1- overexpressing cells to apoptotic stimuli,binds Bcl-2 and Bcl-xL but not Mcl-1
2008,https://doi.org/10.1158/1535-7163.MCT-08-0285,Small molecule mimetic,BH3,obatoclax,"g investigated as an anticancer agent in phase I and II clinical trials on hematologic and lymphoid malignancies as well as small cell and non-small cell lung cancers, sensitizes human cholangiocarcinoma cells to Apo2L/TRAIL by inhibiting Mcl-1
binding to Bak and Bim.",inhibit Mcl-1 in addition to Bcl-2 and Bcl-xL and is predicted to bind in the BH3-binding pocket of Bcl2
2008,https://doi.org/10.1158/1535-7163.MCT-08-0285,phosphomimetic,phosphorylated state of Mcl-1,phosphomimetic Mcl-1 protein (S64E),"use of the S64E protein is biologically relevant, as mouse and rat Mcl-1 wild-type proteins contain a glutamic acid at this position",Noxa binds much more strongly to S64E Mcl-1 than the unphosphorylatable S64A protein
2009,https://doi.org/10.1021/ja810025g,α-helix mimetic,MDM2 (Mouse Double Minute 2 homolog) in its interaction with p53 (Tumor Protein p53),H₂N-Phe-[Trp]-Leu-OH,"designed to inhibit the binding of MDM2 to p53, which is crucial for regulating the cell cycle and preventing tumor formation.","identified as a lead inhibitor with effective activity against MDM2/p53 binding, demonstrating a significant inhibitory effect (IC₅₀ < 50 μM)"
2009,https://doi.org/10.1021/ja810025g,α-helix mimetic,Bak bh3 domain,Hamilton Terphenyl Motif,"mimics the structural and recognition features of an R-helix, facilitating the design of various derivatives.","effectively present side chains at the i, i + 4, and i + 7 positions, which are critical for mimicking the natural interactions of R-helices in proteins"
2009,https://doi.org/10.1161/ATVBAHA.109.187518,Peptide Mimetic,ApoA-I,18A,Mimics the amphipathic helix of ApoA-I,contained 18 amino acids and formed a class A amphipathic helix.
2009,https://doi.org/10.1161/ATVBAHA.109.187518,Peptide Mimetic,ApoA-I,2F,stability and lipid-binding properties were improved,mimicked many of the lipid binding properties of apoA-I but failed to alter lesions in a mouse model of atherosclerosis.
2009,https://doi.org/10.1161/ATVBAHA.109.187518,Peptide Mimetic,ApoA-I,4F,Inhibits inflammation and improves HDL properties,Administered as D-amino acid (D-4F) reduced atherosclerotic lesions in LDL receptor–null and apoE-null mice without altering plasma cholesterol levels. Improved anti-inflammatory properties in various conditions.
2009,https://doi.org/10.1161/ATVBAHA.109.187518,Peptide Mimetic,ApoA-I,5F,Protects against atherosclerosis,L-5F significantly protected mice from diet-induced atherosclerosis and improved HDL's anti-inflammatory properties.
2009,https://doi.org/10.1161/ATVBAHA.109.187518,Peptide Mimetic,ApoA-I,3F14,did not reduce lesion area in apoE-null mice.,Ineffective in scavenging lipid hydroperoxides; did not reduce lesion area in apoE-null mice.
2009,https://doi.org/10.1161/ATVBAHA.109.187518,Peptide Mimetic,ApoA-I,3F-2,gnificantly reduced lesion area in apoE-null mice,gnificantly reduced lesion area in apoE-null mice
2009,https://doi.org/10.1161/ATVBAHA.109.187518,Peptide Mimetic,ApoA-I,4F-P-4F,Enhances HDL remodeling,"Associated with all lipoprotein classes; improved HDL remodeling and cholesterol efflux, but not effective against LDL oxidation compared to single 4F peptide."
2009,https://doi.org/10.1161/ATVBAHA.109.187518,Peptide Mimetic,apoE,Ac-hE-18A-NH2,reduces plasma cholesterol levels in WHHL rabbits and improves arterial endothelial function.,"Changes are associated with reduced plasma lipid hydroperoxide levels, an increase in paraoxonase-1 activity, and a reduction of superoxide anion levels."
2009,https://doi.org/10.1161/ATVBAHA.109.187518,Peptide Mimetic,ApoA-I,37pA,could be used to construct nanoparticles for delivering MRI contrast agent into arteries to elucidate atherosclerotic plaque composition in a mouse model of atherosclerosis.,contrast for the detection of atherosclerotic macrophages even though the larger peptide demonstrated better lipid-binding properties
2009,https://doi.org/10.1161/ATVBAHA.109.187518,Peptide Mimetic,ApoA-I,L-4F,ability to resist enzymatic degradation,"inhibit atherosclerotic lesions , binds niclosamide forming a very tight association that protects the peptide from trypsin digestion allowing L-4F absorption and biological activity after oral administration"
2009,https://doi.org/10.1161/ATVBAHA.109.187518,Peptide Mimetic,ApoA-I,D-4F,ability to resist enzymatic degradation,inhibit atherosclerotic lesions.
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Peptides,Smac,4–8 N-terminal residues of Smac,targets MCF-7 breast cancer cells,"combines with Paclitaxel, etoposide, SN-38,
or doxorubicin"
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Peptides,Smac,4 or 7 N-terminal residues of Smac,targets  Human acute leukemia Jurkat T cells,"combines with Epothilone B derivative
(BMS 247550) or Apo-2L/TRAIL"
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Peptides,Smac,6 N-terminal residues of Smac,targets  HeLa cervical cancer cells,"The 6 N-terminal residues of Smac/DIABLO (specifically residues 1–6) play dual roles in apoptosis regulation: (1) binding to inhibitor of apoptosis proteins (IAPs) via the AVPI motif (residues 1–4), and (2) modulating mitochondrial release through phosphorylation at serine 6 (residue 6)."
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Peptides,Smac,7 N-terminal residues of Smac,targets  L428 and L540 human Hodgkin lymphoma cells,combines with Granzyme B
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Peptides,Smac,7 N-terminal residues of Smac with antenopedia sequence,targets Caki-1 renal carcinoma cells,combines with None or cisplatin
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Peptides,Smac,7 N-terminal residues of Smac conjugated to 8 arginine residues,"targets Suit-2, CFPAC-1, Panc1, and BxPC-3 pancreatic cancer cells (a) H460 non-small-cell lung cancer, (b) H460 xenograft mouse model","combines with (a) Cisplatin or taxol, (b) cisplatin"
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Peptides,Smac,7 N-terminal residues of Smac conjugated to the protein transduction domain of TAT protein,"targets (a) SHEP/Bcl-2 neuroblastoma, SH-SY5Y
neuroblastoma, Mel-HO melanoma, Panc1
pancreatic carcinoma, (b) U87 MG human
malignant glioma xenograft mouse model","combines with (a) TRAIL or doxorubicin, (b) TRAIL"
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Peptides,Smac,Polyvalent naı¨ve phage-derived peptide sequences based on N-terminus of Smac with natural and unnatural amino acid substitutions,targets ML-IAP-overexpressing melanoma cell lines,"The polyvalent naïve phage-derived peptide sequences based on the N-terminus of Smac (Second Mitochondrial Activator of Caspases) with natural and unnatural amino acid substitutions are designed to antagonize Inhibitor of Apoptosis Proteins (IAPs), such as XIAP, to restore caspase-mediated apoptosis in cancer cells"
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Polynucleotides,Smac,Flag-C-tagged mature Smac pcDNA3.1,targets K562 and CEM human leukaemic cells,combines with Ultraviolet light or TRAIL
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Polynucleotides,Smac,Flag-C-tagged full-length Smac,targets NC65 and Caki-1 renal carcinoma cells,combines with TRAIL or cisplatin
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Polynucleotides,Smac,pcDNA3.1,targets Human acute leukemia Jurkat T cells,combines with Epothilone B derivative (BMS 247550) or Apo-2L/TRAIL
2009,https://doi.org/10.1016/j.biomaterials.2008.09.040,Recombinant protein mimetic,Silk and elastin,Silk-Elastin-Like Protein (SELP),Gene delivery,Prolonged and localized expression of adenoviruses for up to 15 days
2009,https://doi.org/10.1016/j.biomaterials.2008.09.040,Triblock copolymer,Elastin,LysB10,"Mechanical responses,  limited local inflammatory activity and displayed relatively thin fibrous capsules.
","Enhanced elastic modulus, reduced creep strain"
2009,https://doi.org/10.1016/j.biomaterials.2008.09.040,Triblock copolymer,Elastin,R4,"Mechanical responses,  limited local inflammatory activity and displayed relatively thin fibrous capsules.
","Enhanced elastic modulus, reduced creep strain"
2009,https://doi.org/10.1016/j.biomaterials.2008.09.040,homopolymers or copolymers,Elastin,VPGVG,Mimics the natural flexibility and biocompatibility of elastin for implant-related applications,Does not induce significant inflammatory or allergic reactions; not recognized as an antigenic epitope of elastin
2009,https://doi.org/10.1016/j.biomaterials.2008.09.040,homopolymers or copolymers,Elastin,VPGKG,"Mimics elastin’s properties, particularly in relation to implant biocompatibility",No significant inflammatory or allergic response reported
2009,https://doi.org/10.1016/j.biomaterials.2008.09.040,homopolymers or copolymers,Elastin,VPGEG,"Used for implant-related applications, mimicking elastin's characteristics",No significant inflammatory response observed
2009,https://doi.org/10.1016/j.biomaterials.2008.09.040,homopolymers or copolymers,Elastin,IPAVG,Mimics the biological properties of elastin in implant contexts,Does not cause significant inflammatory reactions
2009,https://doi.org/10.1016/j.biomaterials.2008.09.040,homopolymers or copolymers,Elastin,VPAVG,"Elastin mimetic, used for subcutaneous and intravitreal injections",No inflammatory response observed after 28 days
2009,https://doi.org/10.1016/j.biomaterials.2008.09.040,homopolymers or copolymers,Elastin,Chemically synthesized poly(GVGVP),"Mimics the structural and functional properties of elastin, used in various implant routes (intravenous, intraocular, intramuscular, etc.)","Did not induce toxicity; no immune response, but a fibrous capsule was noted after intramuscular implantation"
2009,https://doi.org/10.1016/j.biomaterials.2008.09.040,homopolymers or copolymers,Elastin,Chemically synthesized poly(VPAVG),Mimics elastin for implant and injection applications (subcutaneous and intravitreal),"No inflammatory response observed after 28 days, though retinal detachment was noted in some cases"
2009,https://doi.org/10.1007/s11883-009-0008-8,peptide,Apolipoprotein A-I (apoA-I),4F Peptides,Increases formation of pre-β HDL; enhances cholesterol efflux; reduces lipoprotein oxidation; improves antioxidants and vascular repair; reduces renal inflammation,"Improves vasodilation, oxidative stress, myocardial inflammation, and angiogenic potential in various models; reduces adiposity and improves insulin sensitivity in obese mice; improves HDL inflammatory properties in humans with coronary heart disease"
2009,https://doi.org/10.1002/bip.21164,Cyclic ligand-mimetic,Arg-Gly-Asp (RGD) peptide,Cilengitide,"Binds to and inhibits avβ3 and avβ5 integrins, inhibiting endothelial interactions and angiogenesis",Currently in clinical trials for the treatment of glioblastoma
2009,https://doi.org/10.1002/ejoc.200900599,β-Substituted amino acids,Phe’s aromatic side chain,β-MePhe,an increased biological stability of the modified peptides,"comparably higher activity, the activity of short peptides
which are active at the δ-opioid receptor was successfully
altered by exchanging phenylalanine by its β-methylated analogue"
2009,https://doi.org/10.1002/ejoc.200900599,β-Substituted amino acids,"tryptophan residues in α-helical domains of proteins,",β-MeTrp,an increased biological stability of the modified peptides,comparably higher activity
2009,https://doi.org/10.1002/ejoc.200900599,β-Substituted amino acids,L-glutamate,2-(carboxycyclopropyl)-glycine (CCG),used to investigate neuroreceptors activated by L-glutamic acid,L-glutamic acid interacts with different receptors adopting different conformations. This hypothesis was strongly supported by the findings resulting from the use of the CCG diastereomers
2009,https://doi.org/10.1002/ejoc.200900599,side-chain-modified amino acids,tryptophan (Trp) or phenylalanine (Phe),2-naphthylalanine,This compound in combination with other unnatural amino acids can be used for the synthesis of Gonadotropin-releasing hormone (GnRH) antagonists,show a high affinity to the receptor
2009,https://doi.org/10.1002/ejoc.200900599,Proline Analogues,(Trx1P),cis4-Methyl-L-proline,peptide antibiotics,"show antitumor activity as well as a wide antimicrobial spectrum against yeast, fungi and Gram-positive bacteria."
2009,https://doi.org/10.1002/ejoc.200900599,Proline Analogues,collagen,"
trans-4-hydroxy-L-proline",found in human urine as a result of collagen metabolism,"Trans-4-hydroxy-L-proline is a multifunctional imino acid critical for collagen integrity, cellular signaling, stress adaptation, and biomedical applications."
2009,https://doi.org/10.1002/ejoc.200900599,N-methylated peptide,cyclophilin,cyclic undecapeptide cyclosporine A,"one of the most successful drugs (Sandimmun,
Neoral) used after organ transplantations",member of the cyclic peptide immunosuppressants which in addition shows good pharmacological properties and low toxicity.
2009,https://doi.org/10.1002/ejoc.200900599,N-methyl amino acids,"C-terminal region (Phe-Phe-Gly-Leu-Met),",H-Lys-Phe-Ile-Gly-LeuMet-NH2,Using this information the peptidomimetic H-Lys-(Me)- Phe-Ile-Gly-(Me)Leu-Met-NH2 was prepared,Screening of this series of five peptides on the depressor activity of rabbit blood revealed that the modification of Ile and Met lead to inactive compounds while the modification of Phe and Leu showed no effect.
2009,https://doi.org/10.1002/ejoc.200900599,N-methylated peptide,"C-terminal region (Phe-Phe-Gly-Leu-Met),",H-Lys-(Me)- Phe-Ile-Gly-(Me)Leu-Met-NH2,higher resistance against degradation.,full depressor activity
2009,https://doi.org/10.1002/ejoc.200900599,peptoids,ATP-binding motifs in the NACHT domain of NLRP proteins,Ac-NhtrpNharg-Nhtyr-NH2,α-amylase inhibitor.,"as active as their natural models (Ac-Trp-Arg-Tyr-OMe), as an α-amylase inhibitor."
2009,https://doi.org/10.1002/ejoc.200900599,peptoids,α-amylase inhibitory peptide Ac-Trp-Arg-Tyr-OMe,nce Ac-Nhtyr-Nharg-Nhtrp-NH2,The peptoid Ac-Nhtyr-Nharg-Nhtrp-NH₂ is a synthetic α-amylase inhibitor designed to mimic the activity of the natural tripeptide Ac-Trp-Arg-Tyr-OMe,shows an even higher activity than the nature-like forward sequence.
2009,https://doi.org/10.1002/ejoc.200900599,peptaibol,NA,Alamethicin,alternative for the treatment of infections since the resistance to normal antibiotics becomes an increasing medical problem,antimicrobial membrane-active peptide
2009,https://doi.org/10.1002/ejoc.200900599,naturally occurring protease inhibitor,proteins involved in E3 ubiquitin ligase complexes,K-13,"exhibits immunopotentiating activity and were confirmed to have antitumor activity, without showing toxicity",natural non-competitive inhibitor of angiotensin converting enzyme (ACE)
2009,https://doi.org/10.1002/ejoc.200900599,naturally occurring protease inhibitor,NA,OF4949-III,"exhibits immunopotentiating activity and were confirmed to have antitumor activity, without showing toxicity",competitive inhibitor for aminopeptidase B
2009,https://doi.org/10.1002/ejoc.200900599,cyclic derivative,mu-opioid receptors (MOR),"(Tyr-c[-D-Orn-2-Nal-D-Pro-NMe-Ala
",derivative of natural occurring β-casomorphin-5,selective and potent µ-opioid receptor agonist with an IC50 of 35 nM
2009,https://doi.org/10.1080/15419060801891034,Cx-mimetic peptides,Cx43,Gap26,Inhibits CxHc within minutes and gap junctions,"A derivative of Gap 26 specific to Cx37 and Cx40 has proved especially useful in studies of vascular systems (Chaytor et al., 1999) indicating that the peptides are tools that are likely to interact at a common Cx ectodomain communication locus."
2009,https://doi.org/10.1080/15419060801891034,Cx-mimetic peptides,Cx43,Gap 27/43,"Inhibits CxHc within minutes and gap junctions,  may be useful in reducing damage after spinal cord injury.","inhibiting intercellular communication and antigen cross presentation in dendritic cells, T-cell activation and production of immunoglobulins and cytokines in mixed lymphocyte cultures"
2009,https://doi.org/10.1080/15419060801891034,Cx-mimetic peptides,Cx43,Gap 27/40,"Inhibits Cx40 gap junctions,  may be useful in reducing damage after spinal cord injury.","inhibiting intercellular communication and antigen cross presentation in dendritic cells, T-cell activation and production of immunoglobulins and cytokines in mixed lymphocyte cultures"
2009,https://doi.org/10.1080/15419060801891034,Cx-mimetic peptides,cytoplasmic loop (CL) region of connexin 32 (Cx32),Gap24,Inhibits Cx32Hc and not gap junctions,"Gap24 is a peptide that mimics the cytoplasmic loop (CL) region of connexin 32 (Cx32), specifically amino acids 110–121 of Cx32. Its primary activity is to restore the cytosolic Ca²⁺-dependent gating function of mutated Cx32 hemichannels, particularly those affected by the R220X mutation, which causes Charcot-Marie-Tooth disease type 1X (CMT1X)"
2009,https://doi.org/10.1080/15419060801891034,Cx-mimetic peptides,active sites of metalloenzymes,L2 peptide,Influences gap junction channel gating,The L2 peptide from papillomavirus minor capsid protein exhibits several critical activities essential for viral infection and has therapeutic potential as an inhibitor
2009,https://doi.org/10.1146/annurev.med.60.042307.181154,peptide mimetic,TPO,Romiplostim,"bind to and activate the TPO receptor, mimicking natural TPO and stimulating platelet production in the bone marrow. Dimerization of these mimetics enhances receptor activation.","increase platelet production, have a long half-life (120–160 hours), and reduce the risk of immunogenicity by lacking homology with endogenous TPO."
2009,https://doi.org/10.1146/annurev.med.60.042307.181154,Non peptide,TPO,Eltrombopag,ffectively increasing platelet counts in patients with conditions such as immune thrombocytopenic purpura (ITP) and other forms of thrombocytopenia.,"specifically binds to the transmembrane domain of the TPO receptor, activating it to stimulate megakaryocyte proliferation and platelet production"
2009,https://doi.org/10.1016/j.pharmthera.2009.06.002,recombinant fusion protein,GLP-1,Albiglutide (Albugon),"stimulates GLP-1 receptor–dependent
pathways coupled with glucose homeostasis and gastrointestinal motility, improves insulin secretion, and reduces blood glucose","potent anorectic effects in animal studies compared to exenatide and liraglutide, and it is not clear whether this disparity is secondary to the impaired blood–brain barrier's permeability due to the larger molecule and not to albiglutide itself"
2009,https://doi.org/10.1016/j.pharmthera.2009.06.002,glucagon,GLP-1,exenatide,"improves first phase insulin release,  induces a delay of
gastric emptying, and
decreases food intake. It improves the GLUT-4 expression in target
cells of STZ-diabetic rats,  On a long run
B-cell function is improved for which a permanently ongoing
treatment is necessary , treatment of type 2 diabetes","As a GLP-1 agonist, exenatide binds to the pancreatic GLP-1 receptor and improves glucose homeostasis by mimicking the actions of naturally occurring GLP-1, stimulates insulin release in a glucosedependent manner"
2009,https://doi.org/10.1016/j.pharmthera.2009.06.002,glucagon,incretin,Boc5,an oral incretin mimetic,Boc5 is a non-peptidic glucagon-like peptide-1 receptor (GLP-1R) agonist that mimics the activity of the natural incretin hormone GLP-1 (glucagon-like peptide-1)
2009,https://doi.org/10.1158/1535-7163.MCT-09-0493,small-molecule,BH3,HA14-1,promising anticancer agent,able to inhibit the activity of antiapoptotic Bcl-2 family proteins
2009,https://doi.org/10.1080/15419060801891018,peptide,Connexin,Gap24,mimics Connexin,"applied at 200 µM did not affect Cx32E143 channels but reversibly inhibited Panx1 channels, Carboxyfluorescein uptake
by Cx32E143-expressing oocytes was unaffected by it"
2009,https://doi.org/10.1080/15419060801891018,peptide,Connexin,Gap26,mimics Connexin,Inhibition of gap junction channel formation: Cx32E143 +
2009,https://doi.org/10.1080/15419060801891018,peptide,Connexin,Gap27,mimics Connexin,Inhibition of gap junction channel formation: Cx43 +
2009,https://doi.org/10.1080/15419060801891018,peptide,pannexin,Panx1,"“pseudospecificity”, the effect of the Panx1 peptide, like that of the connexinmimetic peptides,","inhibited Cx46 connexon currents, Carboxyfluorescein uptake
by Cx32E143-expressing oocytes was unaffected by it"
2010,https://doi.org/10.1016/j.cbpa.2010.07.017,Synthetic receptor,"
Mutant p53 (p53-R337H)",amphiphilic calixarenes embedded in chromatic phospholipid/polydiacetylene (PDA) vesicles,Induces changes in vesicle absorption spectra,Multivalent interactions
2010,https://doi.org/10.1016/j.cbpa.2010.07.017,Porphyrin-based receptor,"Metaloproteins (e.g., cytochrome c, myoglobin)",TCPP-based receptors,Binding to protein surfaces,Fluorescence quenching upon binding
2010,https://doi.org/10.1016/j.cbpa.2010.07.017,Synthetic polymer,various,Fluorescence quenching upon binding,Protein recognition,Monitoring emission of fluorescently labeled proteins
2010,https://doi.org/10.1016/j.cbpa.2010.07.017,Nanoparticle-based receptor,TAT (HIV transactivator of transcription),Gold nanoparticles conjugated to b-galactosidase,Nanoparticle-based receptor,Disruption of enzyme-NP interaction
2010,https://doi.org/10.1016/j.cbpa.2010.07.017,Nucleic acid-based receptor,red fluorescent protein,DNA G-quadruplexes,Monitoring changes in fluorescence,Changes in emission of fluorophores
2010,https://doi.org/10.4155/fmc.10.259,Peptide-based drug,C-terminal heptad repeat 2 (HR2) region of the HIV-1 gp41 envelope glycoprotein,Fuzeon® (enfuvirtide),HIV fusion inhibitor,"Binds to gp41, prevents HIV from fusing with CD4+ cells, used in cases of drug-resistant HIV strains."
2010,https://doi.org/10.4155/fmc.10.259,Cyclic heptapeptide,barbourin,Integrilin® (eptifibatide),Antiplatelet agent,Prevents ischemic events
2010,https://doi.org/10.4155/fmc.10.259,CCR5 receptor ligand,MIP-1α (CCL3) and MIP-1β (CCL4),RANTES,a 68-mer with N-terminal modifications and non-natural amino acids,substitutions in positions 1–3 to increase potency and protease resistance
2010,https://doi.org/10.4155/fmc.10.259,Lipopeptide antibiotic,NA,Cubicin® (daptomycin),Antibiotic against Gram-positive bacteria,used to treat infection with Grampositive organisms
2010,https://doi.org/10.4155/fmc.10.259,Venom-derived peptide,ω-conotoxin MVIIA,Ziconotide,Chronic pain treatment,s derived from a toxin of the cone snail and has been shown to be effective against chronic pain by blocking calcium-dependent pain signal transmission
2010,https://doi.org/10.4155/fmc.10.259,Venom-derived peptide,NA,Chlorotoxin,capable of blocking chloride channels,"binds exclusively to glioma cells, opening the possibility for treatment and diagnosis of particular cancers."
2010,https://doi.org/10.2174/138920310791330622,Peptide,β-Strand Motifs (PCSK9/LDLR Interaction),Trisubstituted imidazole scaffolds,inhibition of Bcl proteinprotein interactions,disrupt the interaction of Bcl-w and Bak-BH3
2010,https://doi.org/10.2174/138920310791330622,Helical mimetic,Bak BH3 domain,Trispyridylamide scaffold,"antagonist of Bcl-xL,",bifurcated hydrogen-bonding network as well as the minimization of destabilizing conformations allows for the observed geometry
2010,https://doi.org/10.2174/138920310791330622,Helical mimetic,α-helical BH3 domain of the pro-apoptotic protein Bak,Terephthalamide scaffold,antagonist of Bcl-xL,stablilized by an intramolecular hydrogen bond
2010,https://doi.org/10.2174/138920310791330622,Small molecule mimetic,α-helical BH3 domain of the pro-apoptotic protein Bak,"1,4-benzodiazepine-2,5-dione derivatives (BZD)",mimics the critical helical peptide side chains of a known peptide substrate of HDM2,bind to HDM2
2010,https://doi.org/10.2174/138920310791330622,Small molecule mimetic,CDK6,3-hydroxymethylindole,block ligand binding to MAGI3-PDZ2,to block the interaction of PTEN-MAGI3-PDZ2 was investigated via fluorescence polarization
2010,https://doi.org/10.2174/138920310791330622,alpha-helix mimetics,hydrophobic helix D region of CD81,Bisimidazole scaffolds,intramolecular hydrogen bond stabilizes the amide group substituents in a conformation which closely matches the side chain separations on one face of an -helix,utilized to disrupt the interaction of CD81 and HCV-E2.
2010,https://doi.org/10.1126/science.1182749,Peptidomimetic Antibiotics,PG1,L27-11,"spectrum of antimicrobial activity, including minimal inhibitory concentrations (MICs) in the nanomolar range against many Pseudomonas aeruginosa (PA) strains and other Pseudomonas spp.",weakly active or inactive against other Grampositive and Gram-negative bacteria
2010,https://doi.org/10.1126/science.1182749,Peptidomimetic Antibiotics,PG1,L26-19,No fluorescence increase was apparent over 120 min when PA cells were exposed to it,no notable lysis of human red blood cells at concentrations up to 100 mg/ml
2010,https://doi.org/10.1126/science.1182749,Peptidomimetic Antibiotics,β-hairpin loop of protegrin I (PG-1),POL7001,mproved plasma half-lives while retaining a potent and selective action against PA,substantial activity against both strains with calculated median effective doses
2010,https://doi.org/10.1126/science.1182749,Peptidomimetic Antibiotics,β-hairpin structure of protegrin I,POL7080,mproved plasma half-lives while retaining a potent and selective action against PA,substantial activity against both strains with calculated median effective doses
2010,https://doi.org/10.1134/S160767291005011X,dipeptide mimetics,NGF,GK-1,exhibited neuroprotective activity in the concentration range 10–5 to 10–9 M,"at a concentration of 10–5 M attenuated the differentiating effect of NGF by 50%, exhibited the properties
of a tyrosine kinase receptor antagonist"
2010,https://doi.org/10.1134/S160767291005011X,dipeptide mimetics,NGF,GK-2,reduced the viability of neurons and suppressed the neuroprotective effect of GK2 and NGF,"GK2 at a concentration of 10–8 M increased the content of pTrkA, exhibited the properties
of a tyrosine kinase receptor agonist"
2010,https://doi.org/10.1134/S160767291005011X,dipeptide mimetics,NGF,GK-5,"exhibited slight neuroprotective activity; however, they exerted differenti ating properties (caused elongation of PC12 cells and development of outgrowths on them)",increased the amount of heat shock proteins
2010,https://doi.org/10.1134/S160767291005011X,dipeptide mimetics,NGF,GK-6,"exhibited slight neuroprotective activity; however, they exerted differenti ating properties (caused elongation of PC12 cells and development of outgrowths on them)",increased the amount of heat shock proteins
2010,https://doi.org/10.1016/j.addr.2010.04.007,elastin-mimetic triblock copolymer,elastin,B9,Drug delivery,"Monodisperse size distribution, spherical shape"
2010,https://doi.org/10.1016/j.addr.2010.04.007,elastin-mimetic triblock copolymer,elastin,B10,Designed for drug delivery and biomedical applications,"Gel forming temperature is 5 degrees lower than B9  ,Exhibits viscoelastic properties with lower tan δ, indicating a more stable gel structure - Mechanical properties can be tuned through changes in midblock and endblock sizes"
2010,https://doi.org/10.1016/j.addr.2010.04.007,elastin-mimetic triblock copolymer,elastin,C5,Designed for biomedical applications,Gel forming temperature is 14.8 °C <br> - Exhibits lower viscosity compared to B9 <br> - Rheological behavior indicates less viscoelasticity compared to B9
2010,https://doi.org/10.1016/j.addr.2010.04.007,elastin-mimetic triblock copolymer,elastin,LysB10,Designed for drug delivery and biomedical applications,Exhibits elastomeric behavior when chemically cross-linked <br> - Designed for enhanced mechanical properties and potential for drug delivery
2010,https://doi.org/10.1016/j.addr.2010.04.007,elastin-mimetic triblock copolymer,elastin,R4,Designed for drug delivery and biomedical applications,"Exhibits significantly different viscoelastic properties compared to LysB10 due to the more hydrophobic nature of the midblock <br> - Higher tan δ and complex viscosity indicate greater viscoelasticity, making it suitable for specific biomedical applications"
2010,https://doi.org/10.1016/j.biomaterials.2010.02.019,biomimetic,resilin,rec1-resilin,"transformation from globule to coil to extended coil
conformation, thus applications in many areas including biotechnology, medicine, sensors, controlled drug delivery systems and engineering","binding ability of rec1-resilin on a substrate is strongly pH-dependent the protein, adsorbed onto the gold substrate with different orientation depending on pH, such as back-on adsorption at acidic pH of 2, compact end-on bilayer adsorption at the IEP and side-on at high alkaline pH of 12"
2010,https://doi.org/10.1002/jbm.a.32979,peptide,Collagen,Gly-Phe-Hyp-GlyGlu-Arg (GFOGER,"major recognition site for α2β1 integrin binding, promoting robust integrin-mediated cell adhesion, osteoblastic differentiation, and bone repair","promotes α2β1 integrin-mediated cell adhesion, osteoblastic differentiation, and enhances bone repair and implant integration"
2010,https://doi.org/10.1002/jbm.a.32979,peptide,Collagen,DGEA,"a2b1 recognition sequence in type I c,1 although a
different study failed ",inhibits the osteoblastic phenotype of rat bone marrow stromal cells cultured on type I collagen. DGEA-coated hydroxyapatite disks have promoted cell adhesion and upregulated osteoblast marker expression in mesenchymal stem cells in vitro.
2010,https://doi.org/10.1002/jbm.a.32979,peptide,Collagen,P15,"enhances cell adhesion, osteoblastic gene expression, and mineralization on anorganic bone matrix (ABM) in vitro and accelerates early bone formation in porcine and rat cranial defects","improved new bone formation wen implanted into rat tibiae, P15 peptide-coated ABM has also been used in
human periodontal osseous defects resulting in better
clinical outcomes than open flap debridement alone and has
also been used in a pilot clinical study for long-bone
defects"
2010,https://doi.org/10.1111/j.2041-1014.2010.00590.x,peptide,antimicrobial peptides (AMPs),mPE (PMX70004),resulted in a significant reduction of viable C. albicans in this model of Candida infection,"exhibited MIC values below 8 lg ml)1, exhibits the most rapid killing,
with a three-log reduction in CFU after 1–5 min at
50 lg ml)1,  incubated with
C. albicans hyphae, no viable cells were visible at
concentrations higher than 32 lg ml)1 after a 24-h
incubation, indicating that the compound could also kill cells in this form.
. "
2010,https://doi.org/10.1111/j.2041-1014.2010.00590.x,peptide,antimicrobial peptides (AMPs),PMX30016,"no reduction in CFU was observed by 10 min, significant reduction of viable C. albicans in this model of
Candida infection",exhibited MIC values below 8 lg ml)1
2010,https://doi.org/10.1111/j.2041-1014.2010.00590.x,peptide,antimicrobial peptides (AMPs),PMX000519,"PMX000519 is classified as a synthetic antimicrobial peptide (AMP) mimetic, designed to replicate the structure and function of natural antimicrobial peptides",exhibited MIC values below 8 lg ml)1
2010,https://doi.org/10.1111/j.2041-1014.2010.00590.x,peptide,antimicrobial peptides (AMPs),PMX10149,"PMX10149 is a synthetic AMP mimetic with potent antifungal activity against C. albicans, including biofilm-associated infections. Its membrane-targeting mechanism avoids resistance development and enables rapid fungicidal action, making it a promising candidate for treating resistant fungal infections.",exhibited MIC values below 8 lg ml)1
2010,https://doi.org/10.1073/pnas.1004261107,soluble trimeric peptide mimetic,NHR region of the prehairpin intermediate- gp41,IQN17,"mimicks NHR
region of the prehairpin intermediate","NHR-binding inhibitors of HIV-1 infection using mirror image phage display, providing strong evidence that IQN17 presents the NHR region in the same structure as is present in the actual prehairpin intermediate"
2010,https://doi.org/10.1073/pnas.1004261107,peptide,NHR trimer- gp41,IZN36,selection agents with a single-chain antibody variable region (scFv) phage-display library,"IZN36 is a synthetic peptide-based HIV-1 fusion inhibitor designed to block the entry of the virus into host cells by targeting the gp41 protein, a key component of the viral envelope that mediates membrane fusion."
2010,https://doi.org/10.1073/pnas.1004261107,chimeric,gp41,IZN17,Immunogen,dependent on self-association
2010,https://doi.org/10.1073/pnas.1004261107,Peptide,gp41,(CCIZN17)3,"peptide is potentially a better immunogen than IZN17,","trimeric state of the peptide is not dependent on self-association as for IZN17, and the conformational epitope within the hydrophobic pocket is therefore expected to be present even at the highly diluted concentrations resulting from vaccination"
2010,https://doi.org/10.1073/pnas.1004261107,Peptide,gp41,(CCIPN17)3,"to shield the IZ scaffold from immune recognition in an attempt to minimize generation of antibodies against the nonrelevant portion of the peptide chimera, and subsequently focus the immune response against the NHR region. T",binds D5 with an efficiency similar to (CCIZN17)3
2010,https://doi.org/10.1073/pnas.1004261107,Peptide,gp41,(CCIZN36)3,Peptide mimetics of a longer segment of the NHR,elicit neutralizing antibody responses that can be detected in unfractionated serum from guinea pigs. T
2010,https://doi.org/10.1073/pnas.1004261107,Peptide,gp41,(CCIPN36)3,Peptide mimetics of a longer segment of the NHR,elicit neutralizing antibody responses that can be detected in unfractionated serum from guinea pigs. T
2011,https://doi.org/10.1016/j.bbamem.2011.03.016,Membrane protein mimetic,"arious Membrane Proteins (MPs), including integrin β3, transmembrane segments, and apoptotic protein BNip3.",bichelles,Bicelles mimic membrane environments for studying membrane proteins,"Bicelles (bilayered micelles) are dynamic, disc-shaped lipid assemblies that replicate the structure and function of biological membranes, enabling advanced studies of membrane proteins"
2011,https://doi.org/10.1016/j.bbamem.2011.03.016,Membrane protein mimetic,"Cytochrome P450, rhodopsin, voltage-sensing domain of KvAP",Nanodiscs,Reconstitute membrane proteins in a functional form within a stable and flat lipid bilayer,"Facilitate NMR studies of membrane proteins by providing a more native-like environment compared to micelles, with stable and tunable size for better structural and functional analysis."
2011,https://doi.org/10.1016/j.bbamem.2011.03.016,Membrane protein mimetic,"Mitochondrial complex I, human GPCRs (BLT1 and BLT2), bacterial outer membrane proteins (OmpA and OmpX), bacteriorhodopsin, SR calcium ATPase, nicotinic acetylcholine receptor",Amphipols,Short amphipathic polymers that stabilize membrane proteins in aqueous solutions without disrupting their structure.,"Maintains protein solubility and activity, facilitating NMR studies with improved folding yields compared to detergents."
2011,https://doi.org/10.1016/j.bbamem.2011.03.016,Membrane protein mimetic,"Potassium channel KcsA, lipid-anchored proteins (e.g., recoverin, HIV-1 matrix protein)",Reverse Micelles,Encapsulates proteins in a non-polar environment while retaining hydration.,"Used for studying proteins that require a low-viscosity environment, although they may not fully replicate native conditions."
2011,https://doi.org/10.1016/j.bbamem.2011.03.016,Membrane protein mimetic,"Various transmembrane proteins, including EGF receptor, bacteriorhodopsin, magainin, protegrin, Influenza M2 channel, and others",Multilamellar Vesicles,Mimics cellular membranes with multiple lipid bilayers.,"Suitable for solid-state NMR studies, providing a concentrated lipid environment for embedded proteins."
2011,https://doi.org/10.1016/j.cbpa.2011.02.015,b-hairpin mimetics,LptD (outer membrane protein),Bcl-2,Targets outer membrane biogenesis,Inhibits LPS transport to the outer membrane
2011,https://doi.org/10.1016/j.cbpa.2011.02.015,CAMP Mimetics- Cyclic cationic peptide,β-turn regions (containing D-Phe-Pro residues),Gramicidin S,hemolytic properties,Antimicrobial activity
2011,https://doi.org/10.1016/j.cbpa.2011.02.015,CAMP Mimetics- Cyclic cationic peptide,NA,Tyrocidine,hemolytic properties,Antimicrobial activity
2011,https://doi.org/10.1016/j.cbpa.2011.02.015,CAMP Mimetics,NA,b-peptides,Antimicrobial properties,mechanisms differ in effectiveness
2011,https://doi.org/10.1016/j.cbpa.2011.02.015,CAMP Mimetics,Sac7d,Foldamers,Antimicrobial properties,mechanisms differ in effectiveness
2011,https://doi.org/10.1016/j.cbpa.2011.02.015,CAMP Mimetics,NA,Polymers,Antimicrobial properties,mechanisms differ in effectiveness
2011,https://doi.org/10.1016/j.cbpa.2011.02.015,CAMP Mimetics,polyproline type-I-like helices,Peptoids,Antimicrobial properties,mechanisms differ in effectiveness
2011,https://doi.org/10.1016/j.cbpa.2011.02.015,CAMP Mimetics,cathelicidin LL-37,Oligomeric aryl amides,Antimicrobial properties,mechanisms differ in effectiveness
2011,https://doi.org/10.1016/j.cbpa.2011.02.015,CAMP Mimetics,Defensins,Oligomeric aryl ureas,Antimicrobial properties,mechanisms differ in effectiveness
2011,https://doi.org/10.1016/j.cbpa.2011.02.015,b-hairpin peptidomimetic,LptD (OstA/Imp),L27-11,Inhibition of LPS transport,"Non-lytic, potent antimicrobial activity in the nanomolar range against Gram-negative bacteria (Pseudomonas sp)"
2011,https://doi.org/10.1016/j.cbpa.2011.02.015,b-hairpin peptidomimetic,LptD (OstA/Imp),POL7001,Inhibition of LPS transport,"Non-lytic, potent antimicrobial activity in the nanomolar range against Gram-negative bacteria (Pseudomonas sp)"
2011,https://doi.org/10.4049/jimmunol.1002847,Peptide Mimetic,Apolipoprotein E (apoE),COG1410,Immunomodulatory,Reduces TNF-a production; activates PP2A; inhibits NF-kB pathway; enhances PP2A activity in vivo.
2011,https://doi.org/10.4049/jimmunol.1002847,Peptide Mimetic,Apolipoprotein E (apoE),COG112,Immunomodulatory,Reduces activation of the NF-kB pathway; inhibits inflammatory responses.
2011,https://doi.org/10.4049/jimmunol.1002847,Peptide Mimetic,Apolipoprotein E (apoE),apoE[133–149],Immunomodulatory,"uppresses microglial activation and inflammatory mediator secretion (e.g., TNF-a and IL-6); reduces serum TNF-a and IL-6 production in mice treated with LPS."
2011,https://doi.org/10.1016/j.drup.2007.08.002,small-molecule BH3 mimetics,BH3,HA14-1,"Targets leukemia, myeloma, glioblastoma, prostate cancer",Inhibits Bcl-2
2011,https://doi.org/10.1016/j.drup.2007.08.002,small-molecule BH3 mimetics,BH3,BH3-Is,"Targets leukemia, prostate cancer, non-small cell lung cancer",Inhibits Bcl-XL
2011,https://doi.org/10.1016/j.drup.2007.08.002,small-molecule BH3 mimetics,BH3,Antimycin A,Targets leukemia and cervical cancer,"Inhibits Bcl-2, Bcl-XL"
2011,https://doi.org/10.1016/j.drup.2007.08.002,small-molecule BH3 mimetics,BH3,Gossypol,"Targets leukemia, lymphoma, glioblastoma, prostate cancer","Inhibits Bcl-2, Bcl-XL, Mcl-1"
2011,https://doi.org/10.1016/j.drup.2007.08.002,small-molecule BH3 mimetics,BH3,Apogossypol,"Targets leukemia, lymphoma, glioblastoma, prostate cancer","Inhibits Bcl-2, Bcl-XL, Mcl-1"
2011,https://doi.org/10.1016/j.drup.2007.08.002,small-molecule BH3 mimetics,BH3,TW-37,"Targets leukemia, lymphoma, glioblastoma, prostate cancer","Inhibits Bcl-2, Bcl-XL, Mcl-1"
2011,https://doi.org/10.1016/j.drup.2007.08.002,small-molecule BH3 mimetics,BH3,GX015-070,"Targets leukemia, lymphoma, myeloma, lung cancer","Inhibits Bcl-2, Bcl-XL, Mcl-1"
2011,https://doi.org/10.1016/j.drup.2007.08.002,small-molecule BH3 mimetics,BH3,ABT-737,"Targets leukemia, lymphoma, lung cancer, breast cancer","Inhibits Bcl-2, Bcl-XL, Bcl-w"
2011,https://doi.org/10.1021/jm101651b,Bivalent,smac,"(S,3S,3′S,6S,6′S,10aS,10a′S)-N,N′-((1S,1′S)-(1,1′-(1,4- phenylenebis(methylene))bis(1H-1,2,3-triazole-4,1- diyl))bis(phenylmethylene))bis(6-((S)-2-(methylamino)propanamido)-5- oxodecahydropyrrolo[1,2-a]azocine-3-carboxamide)",Induces degradation of cIAP2,Fails to induce caspase-3 processing at 30 nM
2011,https://doi.org/10.1021/jm101651b,Bivalent,smac,"(S,3S,3′S,6S,6′S,10aS,10a′S)-N,N′-((1S,1′S)-(1,1′-(1,4-phenylenebis(ethane-2,1- diyl))bis(1H-1,2,3-triazole-4,1-diyl))bis(phenylmethylene))bis(6-((S)-2- (methylamino)propanamido)-5-oxodecahydropyrrolo[1,2-a]azocine-3- carboxamide)",Induces degradation of cIAP1/2,Limited effect on cIAP1 degradation at 30 nM
2011,https://doi.org/10.1021/jm101651b,Bivalent,smac,"(S,3S,3′S,6S,6′S,10aS,10a′S)-N,N′-((1S,1′S)-(1,1′-(1,4- phenylenebis(propane-3,1-diyl))bis(1H-1,2,3-triazole-4,1- diyl))bis(phenylmethylene))bis(6-((S)-2-(methylamino)propanamido)-5- oxodecahydropyrrolo[1,2-a]azocine-3-carboxamide)",Induces degradation of cIAP1,Induces PARP cleavage and caspase-3 processing
2011,https://doi.org/10.1021/jm101651b,Bivalent,smac,"(S,3S,3′S,6S,6′S,10aS,10a′S)-N,N′-((1S,1′S)-(1,1′-(1,4-phenylenebis(hexane-6,1-
diyl))bis(1H-1,2,3-triazole-4,1-diyl))bis(phenylmethylene))bis(6-((S)-2-
(methylamino)propanamido)-5-oxodecahydropyrrolo[1,2-a]azocine-3-
carboxamide)",Induces degradation of cIAP1/2,Robust activity at low concentrations
2011,https://doi.org/10.1021/jm101651b,Bivalent,smac,"(S,3S,3′S,6S,6′S,10aS,10a′S)-N,N′-((1S,1′S)-(1,1′-(oxybis(pentane-5,1- diyl))bis(1H-1,2,3-triazole-4,1-diyl))bis(phenylmethylene))bis(6-((S)-2- (methylamino)propanamido)-5-oxodecahydropyrrolo[1,2-a]azocine-3- carboxamide)",Antagonist of IAPs,Completely inhibits tumor growth in MDA-MB-231 xenografts
2011,https://doi.org/10.1021/jm101651b,Bivalent,smac,"(3S,6S,10aS)-6-((R)-2-acetamido-3-(1H-indol-3-yl)propanamido)-N-((S)-(1-(4-(4- (4-(4-((S)-((3S,6S,10aS)-6-((R)-2-(methylamino)propanamido)-5- oxodecahydropyrrolo[1,2-a]azocine-3-carboxamido)(phenyl)methyl)-1H-1,2,3- triazol-1-yl)butyl)phenyl)butyl)-1H-1,2,3-triazol-4-yl)(phenyl)methyl)-5- oxodecahydropyrrolo[1,2-a]azocine-3-carboxamide",Several times less potent than the most potent bivalent mimetics,"The compound (3S,6S,10aS)-6-((R)-2-acetamido-3-(1H-indol-3-yl)propanamido)-N-((S)-(1-(4-(4-(4-(4-((S)-((3S,6S,10aS)-6-((R)-2-(methylamino)propanamido)-5-oxodecahydropyrrolo[1,2-a]azocine-3-carboxamido)(phenyl)methyl)-1H-1,2,3-triazol-1-yl)butyl)phenyl)butyl)-1H-1,2,3-triazol-4-yl)(phenyl)methyl)-5-oxodecahydropyrrolo[1,2-a]azocine-3-carboxamide is a bivalent Smac mimetic designed to antagonize inhibitor of apoptosis proteins (IAPs) such as XIAP, cIAP1, and cIAP2. Its activity centers on restoring apoptosis in cancer cells by mimicking the AVPI tetrapeptide motif of the Smac protein, which naturally binds IAPs to neutralize their anti-apoptotic effects."
2011,https://doi.org/10.1038/onc.2011.104,Small molecule mimetic,BH3,ABT737,"induces autophagy by competitively disrupting the inhibitory interaction between the BH3 domain of Beclin 1 and the anti-apoptotic proteins Bcl-2 and Bcl-XL, thereby stimulating the Beclin 1-dependent allosteric activation of the pro-autophagic lipid kinase VPS34","caused the activating phosphorylation of AMP-dependent kinase (AMPK) and of the AMPK substrate acetyl CoA carboxylase, the activating phosphorylation of several subunits of the inhibitor of NF-jB (IjB) kinase (IKK) and the hyperphosphorylation of the IKK substrate IjB, inhibition of the activity of mammalian target of rapamycin (mTOR) and consequent dephosphorylation of the mTOR substrate S6 kinase. In addition, ABT737 treatment dephosphorylates (and hence likewise inhibits) p53, glycogen synthase kinase-3 and Akt"
2011,https://doi.org/10.1038/onc.2011.104,Small molecule mimetic,BH3,HA14-1,highly efficient in inducing autophagy including in U2OS and HeLa cells,"induced LC3 lipidation, p62 degradation and GFP-LC3 redistribution to autophagic dots in control and Bax/Bak/ double-knockout MEFs similarly"
2011,https://doi.org/10.1517/14728222.2011.640319,peptide,TSP1,ABT-510,"anti-angiogenic at low nanomolar concentrations,  promising, but compromised by its short half life",blocks angiogenesis and cancer progression in multiple preclinical models
2011,https://doi.org/10.1517/14728222.2011.640319,peptide,TSP1,ABT-526,potent anti-angiogenic activity and clearance sufficient to allow testing in pre-clinical tumor models.,"Because of its slower clearance in primates, and higher water solubility the D-alloIle peptide, ABT-510 was chosen over its enantiomer, ABT-526, for human trials."
2011,https://doi.org/10.1517/14728222.2011.640319,peptide,TSP1,ABT-898,more stable and more potent,"active in the preclinical models of cancer, inflammatory disease and eye disease"
2011,https://doi.org/10.1016/j.ijmm.2010.04.020,synthetic heme– protein,peroxidase,"FeIII–mimochrome VI,","catalytic efficiency is comparable to that of native
horseradish peroxidase","By the use of hydrogen peroxide, FeIII–mimochrome VI efficiently catalyzes the oxidation of several substrates, with a typical Michaelis–Menten mechanism and with several multiple turnovers , converts
phenol to 4- and 2-nitrophenol in the
presence of NO2
 and H2O2 in high
yields. T"
2011,https://doi.org/10.1177/1947601911417177,small molecule,BH3,ABT-737,"Phases I and II: leukemia, lymphoma, myeloma, small cell lung cancer, cervical cancer, breast cancer","Binding to BCL-2 Members: Ki for BCL-2 = 1 nM
Ki for BCL-xL = 0.5 nM
Ki for BCL-w = 1 nM
Ki for MCL-1 = 550 nM"
2011,https://doi.org/10.1177/1947601911417177,small molecule,BH3,ABT-263,"n reported to have the strongest binding affinities to
anti-apoptotic members of the BCL-2 family when compared to other BH3 mimetics., Phases I and II: leukemia, lymphoma, myeloma, small cell lung cancer, cervical cancer, breast cancer","Binding to BCL-2 Members: Ki for BCL-2 = 1 nM
Ki for BCL-xL = 0.5 nM
Ki for BCL-w = 1 nM
Ki for MCL-1 = 550 nM"
2011,https://doi.org/10.1177/1947601911417177,small molecule,BH3,Apogossypol,Preclinical,". BCL-2 Family Inhibitor: Ki
 for BCL-2 = 35 nM
Ki
 for BCL-xL = 660 nM
Ki
 for MCL-1 = 25 nM"
2011,https://doi.org/10.1177/1947601911417177,small molecule,BH3,(–)Gossypol,"Phases I and II: chronic lymphocytic leukemia, non-Hodgkin lymphoma, glioblastoma, head and neck, prostate cancer, small cell lung cancer","bind BCL-2, BCL-xL, and MCL-1 although with affinities
that are much lower than of the BH3-only proteins to these
proteins, BCL-2 Family Inhibitor: Ki
 for BCL-2 = 320 nM
Ki
 for BCL-xL = 480 nM
Ki
 for MCL-1 = 180 nM"
2011,https://doi.org/10.1177/1947601911417177,small molecule,BH3,GX-15-070,"Phase I: leukemia, lymphoma, multiple myeloma, non–small cell lung cancer",". BCL-2 Family Inhibitor: Ki
 for BCL-2 = 220 nM
Ki
 for BCL-xL = 0.5 µM
Ki
 for MCL-1 = 0.5 µM"
2011,https://doi.org/10.1177/1947601911417177,small molecule,BH3,HA14-1,"Preclinical, s shown to induce apoptosis
in leukemic and lymphocytic cells as well as sensitize glioblastoma cells to apoptosis","o inhibit the binding of BCL-2 and
BCL-xL to BAK and BAX, as well as the direct activator
BIM, BCL-2 Family Inhibitor: Ki
 for BCL-2 = 9 µM"
2011,https://doi.org/10.1177/1947601911417177,small molecule,BH3,TW-37,"Phases I and II: chronic lymphocytic leukemia, non-Hodgkin lymphoma, glioblastoma, head and neck cancer, prostate cancer, small cell lung cancer",BCL-2 Family Inhibitor: Ki for BCL-2 = 290 nM Ki for MCL-1 = 260 nM
2011,https://doi.org/10.1177/1947601911417177,transmembrane protein,BH3,TM-106,Gossypol derivative,"TM106 inhibits the release of enveloped viruses (e.g., HIV-1) by trapping virions at the cell surface through interactions with its C-terminal domain."
2012,https://dx.doi.org/10.2174/138955712803832690,Glycomimetic,"1,2-mannobioside","Pseudo-1,2-mannobioside+F2:F155","Pseudo-1,2-mannobioside  acts as a mimic of a reducing end mannose residue and features a spacer-arm terminated with azido or amino functionality, useful to generate multivalent DC-SIGN ligands.","Mimics mannose to interact with DC-SIGN receptors, aiding in pathogen adhesion studies."
2012,https://dx.doi.org/10.2174/138955712803832690,Glycomimetic,"linear Man (1,2)Man (1,6)Man trisaccharide","pseudo-trisaccharide, 2","This compound inhibits DC-SIGN binding to mannosylated BSA (Bovine serum albumin) with an IC50 of 130 M (by surface-plasmon resonance, SPR).","Potential anti-infective agent by blocking DC-SIGN receptor interactions, which could inhibit pathogen entry and infection processes"
2012,https://doi.org/10.1016/j.bmcl.2012.04.014,Glycomemitics,Heparan Sulphate,PI-88,"a highly sulfonated oligosaccharide that mimics heparan sulfate and has potent anti-angiogenic activity, currently in clinical trials","Inhibits heparanase activity and angiogenesis, showing potential as an anti-cancer and anti-metastatic agent."
2012,https://doi.org/10.1016/j.bmcl.2012.04.014,Glycomemitics,Heparan Sulphate,Small molecule fluoro-xylosides,"small molecules that mimic heparan sulfate and potently reduce tumor-associated angiogenesis by inhibiting HS biosynthesis in vitro, requiring cellular entry to be effective","Disrupts HS biosynthesis, leading to reduced tumor angiogenesis and potential anti-cancer applications."
2012,https://doi.org/10.1016/j.bmcl.2012.04.014,Glycomemitics,Heparan Sulphate,Polysulfonated small molecules,"these mimic heparin/heparan sulfate and act as inhibitors of angiogenesis, identified as promising in vitro tube formation assay inhibitors and can be easily synthesized","Prevents angiogenesis by inhibiting heparan sulfate interactions, making them potential therapeutic agents for cancer treatment."
2012,https://doi.org/10.2174/138955712803832672,Aminoglycoside antibiotic,Streptamine-based pseudo-oligosaccharide,Streptomycin,Binds to the 30S subunit of ribosomal RNA (rRNA) to inhibit protein synthesis.,Effective against Mycobacterium tuberculosis
2012,https://doi.org/10.2174/138955712803832672,Aminoglycoside antibiotic,2-Deoxystreptamine (2-DOS) based pseudo-oligosaccharide,Neomycins,Binds to rRNA to prevent normal translation of proteins.,Broad-spectrum antibiotic activity
2012,https://doi.org/10.2174/138955712803832672,Aminoglycoside antibiotic,2-Deoxystreptamine (2-DOS) based pseudo-oligosaccharide,Paramomycins,Binds to rRNA to inhibit protein synthesis.,Broad-spectrum antibiotic activity
2012,https://doi.org/10.2174/138955712803832672,Aminoglycoside antibiotic,2-Deoxystreptamine (2-DOS) based pseudo-oligosaccharide,Kanamycins,Binds to rRNA to inhibit protein synthesis.,Broad-spectrum antibiotic activity
2012,https://doi.org/10.2174/138955712803832672,Aminoglycoside antibiotic,2-Deoxystreptamine (2-DOS) based pseudo-oligosaccharide,Gentamicins,Binds to rRNA to inhibit protein synthesis.,Broad-spectrum antibiotic activity
2012,https://doi.org/10.2174/138955712803832672,Aminoglycoside antibiotic,2-Deoxystreptamine (2-DOS) based pseudo-oligosaccharide,Tobramycins,Binds to rRNA to inhibit protein synthesis.,Broad-spectrum antibiotic activity
2012,https://doi.org/10.2174/138955712803832672,Semi-synthetic aminoglycoside antibiotic,2-Deoxystreptamine (2-DOS) based pseudo-oligosaccharide,Amikamycins,Binds to rRNA to inhibit protein synthesis.,"Effective against resistant bacteria, particularly Gram-negative pathogens"
2012,https://doi.org/10.2174/138955712803832672,Semi-synthetic aminoglycoside antibiotic,2-Deoxystreptamine (2-DOS) based pseudo-oligosaccharide,Dibekacins,Binds to rRNA to inhibit protein synthesis.,"Active against aminoglycoside-resistant strains, used for treating severe infections"
2012,https://doi.org/10.2174/138955712803832672,Semi-synthetic aminoglycoside antibiotic,2-Deoxystreptamine (2-DOS) based pseudo-oligosaccharide,Sisomicins,Binds to rRNA to inhibit protein synthesis.,"Broad-spectrum activity, effective against Pseudomonas aeruginosa and other resistant pathogens"
2012,https://doi.org/10.2174/138955712803832672,Semi-synthetic aminoglycoside antibiotic,2-Deoxystreptamine (2-DOS) based pseudo-oligosaccharide,Netilmicins,Binds to rRNA to inhibit protein synthesis.,"Active against aminoglycoside-resistant bacteria, lower ototoxicity compared to other aminoglycosides"
2012,https://doi.org/10.1155/2012/740982,GD1α-mimetic peptide,GD1α (a ganglioside),GD1 α-mimetic peptides,"These peptides functionally mimic GD1α, which is an adhesion molecule involved in tumor metastasis.",GD1α-replica peptides suppress tumor metastasis.
2012,https://doi.org/10.1155/2012/740982,Oligosaccharide-mimetic peptide,Sialyl-Lewis X (sLeX),sLe X-mimetic peptides,"These peptides inhibit binding to E-selectin, which is involved in cell adhesion processes.","inhibit the binding of E-selectin, thereby reducing neutrophil rolling and adhesion to endothelial cells during inflammatory responses."
2012,https://doi.org/10.1155/2012/740982,Peptide mimetic,α-Gal (Galα1-3Gal),Peptide mimetics of xenoreactive α-Gal antigenic epitope,"These mimetics are designed to mimic the α-Gal epitope, which is known to elicit strong immune responses in humans, particularly in the context of xenotransplantation.","The peptide mimetics can potentially inhibit the binding of anti-α-Gal antibodies, thereby reducing the risk of hyperacute rejection in xenotransplantation scenarios."
2012,https://doi.org/10.1593/neo.111544,Carbohydrate-based galectin inhibitor,Galactoside-containing polysaccharide,Modified Citrus Pectin (MCP),"Inhibits galectin-3, blocking its antiapoptotic function and tumor cell clonogenic survival","Shown to inhibit experimental metastasis in various animal models, including melanoma and prostate carcinoma"
2012,https://doi.org/10.1593/neo.111544,Synthetic β-galactoside disaccharide/amino acid conjugate,Cancer-associated Thomsen-Friedenreich antigen (TF-Ag),Glycoamine Lactulose-L-leucine (Lac-L-Leu),"Binds and inhibits galectin-3, mimicking TF-Ag",Impedes metastasis-associated tumor cell adhesive interactions and inhibits the formation of early metastatic deposits in lungs and bones
2012,https://doi.org/10.1371/journal.pone.0035457,Carbohydrate mimetic peptide,GD2 ganglioside,Peptides mimicking GD2 ganglioside,"These peptides are designed to mimic the structure of GD2 ganglioside, which is a tumor-associated antigen.","They elicit immune responses, including cellular and humoral immunity, and can potentially be used in cancer immunotherapy"
2012,https://doi.org/10.1371/journal.pone.0035457,Carbohydrate mimetic peptide,GD3 ganglioside,Peptides mimicking GD3 ganglioside,"Similar to GD2 mimics, these peptides replicate the structure of GD3 ganglioside, facilitating recognition by specific antibodies.","They can induce anti-ganglioside immune responses, contributing to the development of therapeutic strategies against cancers expressing GD3"
2012,https://doi.org/10.1016/j.carres.2012.05.024,Carbohydrate Mimetic,Pentasaccharide,Octapeptide 2,Binds to the SYA/J6 antibody with moderate affinity,"Potential use in developing vaccines or therapeutics targeting diseases where pentasaccharide recognition plays a role, such as certain bacterial infections or autoimmune disorders"
2012,https://doi.org/10.1016/j.carres.2012.05.024,Glycopeptide mimetic,Structural elements from the pentasaccharide and the octapeptide,a-Glycopeptide 3,"Designed to mimic natural antigens for vaccine development. Interacts with the antibody primarily on the periphery of the combining site, with some residues maintaining interactions similar to those in the pentasaccharide","Potential use in vaccine development against pathogens that express similar carbohydrate structures, possibly including certain bacterial strains or parasites. May also have applications in autoimmune diseases where antibodies against specific carbohydrate structures are involved."
2012,https://doi.org/10.1016/j.carres.2012.05.024,Glycopeptide mimetic,Structural elements from the pentasaccharide and the octapeptide,b-Glycopeptide 4,Designed to mimic natural antigens for vaccine development,Potential use in vaccine development against pathogens expressing similar carbohydrate structures. May also have applications in treating autoimmune diseases where antibodies against specific carbohydrate structures are involved.
2012,DOI: 10.2174/138955712803832753,Synthetic carbohydrate mimetic,GDP-fucose,GDP-hexanolamine,Inhibitors of fucosyltransferases,"Potential treatment for cancer and inflammatory diseases by inhibiting fucosylation processes involved in cell-cell recognition, cell adhesion, and signaling pathways"
2012,DOI: 10.2174/138955712803832753,Synthetic carbohydrate mimetic,Trisaccharide	,Azatrisaccharide containing a piperidine ring,Inhibitor of glycosyltransferases,Potential treatment for cancer and inflammatory diseases by inhibiting aberrant glycosylation processes
2012,DOI: 10.2174/138955712803832753,Synthetic carbohydrate mimetic,N-Ac-lactosamine,N-Ac-lactosamine mimetics,Inhibitor of glycosyltransferases,Potential treatment for cancer and inflammatory diseases by inhibiting aberrant glycosylation processes
2012,https://doi.org/10.1371/journal.pone.0043976,Ganglioside mimic,GM1 ganglioside,GM1,"Induces antibodies that may cross-react with neural tissue, contributing to the pathogenesis of Guillain-Barré syndrome (GBS)","Found in the lipo-oligosaccharides (LOS) of C. jejuni strains associated with GBS, indicating a role in immune response"
2012,https://doi.org/10.1371/journal.pone.0043976,Ganglioside mimic,GD1a ganglioside,GD1a,"Similar to GM1, it induces antibodies that may cross-react with neural tissue, contributing to GBS","Detected in the lipooligosaccharide (LOS) of C. jejuni strains related to Guillain-Barré syndrome (GBS), indicating its involvement in triggering an autoimmune response that leads to peripheral nerve damage and acute flaccid paralysis"
2012,https://doi.org/10.1371/journal.pone.0043976,Ganglioside mimic,GA2 ganglioside,GA2,Associated with the immune response in patients with ophthalmoplegia,"Structures mimicking GA2 were found in LOS of C. jejuni strains associated with GBS, suggesting a role in pathogenic antibody formation"
2012,https://doi.org/10.1371/journal.pone.0043976,Ganglioside mimic,GD3 ganglioside,GD3,"Similar to GA2, it is involved in the immune response related to GBS","Structures mimicking GD3 were also found in LOS of C. jejuni strains associated with GBS, indicating their role in inducing pathogenic antibodies"
2012,https://doi.org/10.1093/glycob/cwr140,Carbohydrate-Mimetic Peptides,Methyl α-D-mannopyranoside (a known carbohydrate ligand for Con A).,Con A Ligand-Mimetic Peptides,Serve as ligands for the lectin concanavalin A (Con A).,"Potential applications in antiviral therapy, cancer treatment, and as vaccine components by mimicking carbohydrate antigens and inducing immune responses"
2012,https://doi.org/10.1093/glycob/cwr140,Carbohydrate-Mimetic Peptides,Non-reducing terminal galactose structure.,9-mer Peptides,Recognized by monoclonal antibodies directed to lacto-tetraosylceramide and neolactotetraosylceramide. Bind to Ricinus lectin and inhibit Jack bean β-galactosidase activity toward neolactotetraosylceramide,Potential applications in cancer therapy and treatment of infectious diseases by mimicking carbohydrate antigens and modulating galactose-mediated cellular processes
2012,https://doi.org/10.1093/glycob/cwr140,Carbohydrate-Mimetic Peptides,Lewis Y antigen.,PWLY Peptide,Induces an immune response against the Lewis Y antigen.,"Can elicit an immune response in rabbits and mice, demonstrating its potential as a vaccine component"
2012,https://doi.org/10.1093/glycob/cwr140,Carbohydrate-Mimetic Peptides,Sialyl Lewis X (a carbohydrate ligand).,I-Peptide (IELLQAR),Inhibits the binding of sialyl Lewis X to E-selectin.,"Inhibits lung colonization of melanoma cells, potentially useful for cancer metastasis prevention. May also have applications in treating inflammatory conditions and modulating immune responses."
2012,https://doi.org/10.1093/glycob/cwr140,Carbohydrate-Mimetic Peptides (Epitope analog.),Type III capsular polysaccharide of group B streptococci (GBS).,FDTGAFDPDWPA Peptide,Elicits an antibody response against GBS.,"When conjugated to carriers and used for immunization, it resulted in a significant antibody response to GBS after a single immunization"
2013,https://doi.org/10.1002/ejoc.201201413,Iminosugar,maltose,N-hydroxyethyl-1-deoxy-nojirimycin (Glyset),Glycosidase inhibitor,"Used primarily in the treatment of Type 2 diabetes by inhibiting α-glucosidase, which slows carbohydrate absorption."
2013,https://doi.org/10.1002/ejoc.201201413,Iminosugar,glucosamine,N-butyl-1-deoxy-nojirimycin (Zavesca),Glycosidase inhibitor,"Approved for the treatment of Type 1 Gaucher disease, acting as a pharmacological chaperone for mutant glucocerebrosidase."
2013,https://doi.org/10.1002/ejoc.201201413,Iminosugar,glucose,1-deoxynojirimycin (DNJ),Glycosidase inhibitor,Inhibits various glycosidases and has potential therapeutic applications in metabolic disorders.
2013,https://doi.org/10.1002/ejoc.201201413,Iminosugar,Mannitol,"1,5-dideoxy-1,5-imino-D-mannitol",Glycosidase inhibitor,"Potential treatment for viral infections (HIV, influenza), metabolic disorders (diabetes), and cancer by inhibiting specific glycosidases involved in carbohydrate processing"
2013,https://doi.org/10.1002/ejoc.201201413,Iminosugar,Glucitol (Sorbitol),"1,5-Dideoxy-1,5-imino-D-glucitol",Acts as a glycosidase inhibitor.,"Inhibits enzymes such as α-glucosidases, which are involved in the hydrolysis of glycosidic bonds in carbohydrates. This inhibition can help regulate blood sugar levels, making it useful in the management of diabetes and related metabolic disorders."
2013,https://doi.org/10.1002/ejoc.201201413,Iminosugar,Lyxose,"1,5-Dideoxy-1,5-imino-D-lyxitol",Acts as a glycosidase inhibitor.,"Inhibits glycosidases, which can affect carbohydrate metabolism. Its structural similarity to lyxose allows it to interfere with the enzymatic processes that normally act on this sugar, potentially providing therapeutic benefits in conditions related to carbohydrate metabolism."
2013,https://doi.org/10.1002/ejoc.201201413,Iminosugar,Idohexose,1-Deoxy-1-idonojirimycin (l-DIJ),Glycosidase inhibitor,"Inhibits enzymes involved in carbohydrate metabolism, potentially useful in treating metabolic disorders."
2013,https://doi.org/10.1002/ejoc.201201413,Iminosugar,Pentoses,1-C-alkyl iminopentitols,Glycosidase inhibitor,"Potent inhibitors of β-glucocerebrosidase, showing potential as therapeutic agents for Gaucher disease."
2013,https://doi.org/10.1002/ejoc.201201413,Iminosugar,Mannitol,"1,5,6-trideoxy-1,5-imino-D-mannitol",Glycosidase inhibitor,"Inhibits glycosidases, potentially useful in therapeutic applications."
2013,https://doi.org/10.1002/ejoc.201201413,Iminosugar,Glucitol,"1,5,6-trideoxy-1,5-imino-D-glucitol",Glycosidase inhibitor,"Inhibits glycosidases, impacting carbohydrate metabolism."
2013,https://doi.org/10.1039/C3PY01123B,b-1/6-linked N-acetylglucosamine Oligosaccharide,Polysaccharide intercellular adhesin (PIA) produced by Staphylococcus aureus,Compound 5 (per-acetylated b-1/6-linked N-acetylglucosamine disaccharide),"To create a surface that mimics the natural biofilm structure, enhancing immune recognition.","Potentially immunogenic, may produce anti-PNAG antibodies in vivo, aiding in vaccine development against Staphylococcus aureus infections, particularly biofilm-associated infections"
2013,https://doi.org/10.1039/C3PY01123B,b-1/6-linked N-acetylglucosamine Oligosaccharide,Polysaccharide intercellular adhesin (PIA) produced by Staphylococcus aureus,Oligosaccharides 6-8 (various benzoylated b-1/6-linked glucosamine-based oligosaccharides),Present multiple copies of carbohydrate units to probe multivalent interactions.,"Mimics the globular nodules of PIA, facilitating studies on bacterial adhesion and immune response."
2013,https://doi.org/10.1039/C3PY01123B,Multivalent Constructs,Polysaccharide intercellular adhesin (PIA) produced by Staphylococcus aureus,Multivalent Carbohydrate Constructs,Present multiple copies of carbohydrate units to enhance immune engagement.,"Potential vaccine candidate against Staphylococcus aureus infections by mimicking PIA structure, inducing antibody production, and enhancing immune response against biofilm-associated infections"
2013,https://doi.org/10.1007/128_2013_498,Oligosaccharide Mimetic,Neu5Ac-α(2–3)-Gal-β(1–3)-GalNAc,Neu5Ac-α(2–3)-Gal-β(1–3)-[Neu5Ac-α(2–6)]-GalNAc-β-OSE,"Acts as a high-affinity ligand for MAG, blocking its binding site.","Inhibits MAG (Myelin-Associated Glycoprotein)-mediated neuronal growth inhibition, potentially aiding in nerve regeneration."
2013,https://doi.org/10.1007/128_2013_498,Oligosaccharide Mimetic,Neu5Ac-α(2–3)-Gal-β(1–3)-Gal,Neu5Ac-α(2–3)-Gal-β(1–3)-[Neu5Ac-α(2–6)]-Gal-β-OSE,Designed to mimic the binding characteristics of sialylated gangliosides.,"Competes with natural sialoglycans to disrupt MAG binding, aiding in neuroprotection."
2013,https://doi.org/10.1007/128_2013_498,Oligosaccharide Mimetic,Neu5Ac-α(2–3)-Gal-β(1–3)-GalNAc,Neu5Ac-α(2–3)-Gal-β(1–3)-GalNAc-β-OSE,Serves as a competitive inhibitor for MAG binding.,"Prevents MAG from interacting with its natural ligands, promoting neurite outgrowth."
2013,https://doi.org/10.1007/128_2013_498,Oligosaccharide Mimetic,Neu5Ac-α(2–3)-Gal-β(1–3)-Gal,Neu5Ac-α(2–3)-Gal-β(1–3)-Gal-β-OSE,Mimics the sialylated structure to inhibit MAG interactions.,"Blocks MAG function, potentially aiding in nerve repair and regeneration"
2013,https://doi.org/10.1007/128_2013_498,Oligosaccharide Mimetic,Gal-β(1–3)-[Neu5Ac-α(2–6)]-Gal,Gal-β(1–3)-[Neu5Ac-α(2–6)]-Gal-β-OSE,Designed to block MAG binding through structural similarity.,"Disrupts MAG-mediated inhibition, facilitating neuronal regeneration."
2013,DOI: 10.1248/yakushi.13-00054,α-1-C-alkyl-arabinoiminofuranoses,Various carbohydrates,α-1-C-alkyl-arabinoiminofuranoses,Inhibitor of intestinal maltase and sucrase,"Showed potent inhibitory activities towards intestinal maltase, with IC50 values comparable to commercial drugs such as acarbose, voglibose, and miglitol,which are used in the treatment of type 2 diabetes"
2013,https://doi.org/10.1002/chem.201302786,GM1 mimetics,GM1 ganglioside,Pseudo-tetrasaccharides bearing a cyclohexane diol moiety,Binds to cholera toxin with high affinity,"Potential inhibitor of cholera toxin, which could prevent cholera infection by blocking toxin binding to intestinal cells"
2013,https://doi.org/10.1002/chem.201302786,Non-carbohydrate mimics,GM1 ganglioside,Based on a polyhydroxyalkylfuroic ester structure,Act as antagonists of enterotoxins,Showed binding affinities in the same order as known sugar-derived MNPG; the highest affinity was shown by these non-carbohydrate mimics towards cholera toxin
2013,https://doi.org/10.1002/anie.201302543,Carbocyclic analogue of sergliflozin,"Sergliflozin, which is a glucose analogue",Pseudo-sergliflozin,"Acts as a selective inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), responsible for glucose reabsorption in the kidneys.","Pseudo-sergliflozin has a three-fold longer half-life and longer hypoglycemic action compared to sergliflozin-A (2b) in db/db mice, indicating its potential effectiveness as an antidiabetic agent"
2013,https://doi.org/10.1002/anie.201302543,Original sergliflozin compound,Glucose,Sergliflozin-A,"Inhibitor of SGLT2, similar to pseudo-sergliflozin.",Potential treatment for type 2 diabetes by increasing urinary glucose excretion and lowering blood glucose levels without causing hypoglycemia
2014, https://doi.org/10.3762/bjoc.10.17,Carbohydrate memitics,Septanosides,Poly(hydroxy)aminooxepanes derivatives.,Potentially serve as selectin inhibitors and can be used in multivalent conjugates.,Potential therapeutic applications in inflammatory conditions and vascular diseases by inhibiting P- and L-selectin mediated cell adhesion
2014,https://doi.org/10.3389/fimmu.2014.00308,"natural peptides derived from proteins, such as those from the Mucin 1 cell surface receptor (MUC1), which are considered mimics of carbohydrate antigens like the Gal-epitope",Gal-epitope,carbohydrate-mimetic peptides (CMPs),"inducing immune responses to glycan antigens expressed on cancer cells and pathogens, mediating cognate B and T-cell interactions, and potentially functioning as probes to understand the structural basis for the dual recognition properties of antibodies, lectins, and T cells","inducing immune responses that can inhibit tumor growth in vivo, generating antibodies capable of neutralizing pathogens such as HIV-1, and mediating cytotoxic activity against tumor cells."
2014,https://doi.org/10.3762/bjoc.10.182,β-D-2-aminotalose-configured carbohydrate mimetics,"structures related to aminopyrans, which can be associated with various natural carbohydrates, including those with β-D-talose and β-D-idopyranose configurations",phenyl-substituted aminopyrans,"The function of phenyl-substituted aminopyrans includes serving as potential inhibitors for selectins, which are important in cell adhesion processes",Potential anti-inflammatory and anti-metastatic effects due to high binding affinities towards L- and P-selectin when presented in a multivalent format
2014, https://doi.org/10.3762/bjoc.10.182,β-D-2-aminotalose-configured carbohydrate mimetics,structures related to β-D-2-aminotalose and β-D-2-aminoidose,rigid divalent p-terphenyl-linked carbohydrate mimetics,"the function of these mimetics includes serving as potential inhibitors for selectins, which are important in cell adhesion processes","The activity of rigid divalent p-terphenyl-linked carbohydrate mimetics is highlighted by their ability to exhibit high binding affinities towards L- and P-selectin when presented in a multivalent format, indicating their potential biological activity ."
2014, https://doi.org/10.3762/bjoc.10.182,β-D-2-aminoidose-configured carbohydrate mimetics,mimic structures related to β-D-2-aminotalose and β-D-2-aminoidose,divalent compounds with p-terphenyl spacers,"the function of these mimetics includes serving as potential inhibitors for selectins, which are important in cell adhesion processes",Potential anti-inflammatory and anti-metastatic effects due to high binding affinities towards L- and P-selectin when presented in a multivalent format
2014, https://doi.org/10.3762/bjoc.10.182,Unnatural divalent rigid p-terphenyl-linked C-aryl glycosides,structures related to β-D-2-aminotalose and β-D-2-aminoidose,biphenyl aminopyran,"the function of these mimetics includes serving as potential inhibitors for selectins, which are important in cell adhesion processes",Potential anti-inflammatory and anti-metastatic effects due to high binding affinities towards L- and P-selectin when presented in a multivalent format
2014, https://doi.org/10.3762/bjoc.10.182,Unnatural divalent rigid p-terphenyl-linked C-aryl glycosides,structures related to β-D-2-aminotalose and β-D-2-aminoidose,p-terphenyl-linked dimers,"the function of these mimetics includes serving as potential inhibitors for selectins, which are important in cell adhesion processes",Potential anti-inflammatory and anti-metastatic effects due to high binding affinities towards L- and P-selectin when presented in a multivalent format
2014, https://doi.org/10.3762/bjoc.10.182,carbohydrate mimetics that combine features of C-aryl glycosides and aminosugars,structures related to β-D-2-aminotalose and β-D-2-aminoidose,Aminosugar Mimetics,"the function of these mimetics includes serving as potential inhibitors for selectins, which are important in cell adhesion processes",Potential inhibition of selectin-mediated cell adhesion
2014,https://doi.org/10.1002/ejoc.201402191,carbohydrate mimetics.,natural carbohydrate Sialyl Lewis X.,"Sialyl Lewis X (sLe x) analogues
",these analogues have the potential to be used for the treatment of diseases such as chronic inflammations.,"They are involved in high binding affinities towards L- and P-selectins, which are important in cell adhesion processes"
2014,https://doi.org/10.1002/ejoc.201402191,carbohydrate mimetics.,Septanosides,Poly(hydroxy)aminooxepanes,"The function of poly(hydroxy)aminooxepanes is to serve as building blocks for the synthesis of various compounds, including those considered as carbohydrate mimetics","Potential therapeutic applications in inflammatory conditions and vascular diseases by inhibiting P- and L-selectin mediated cell adhesion. May have interesting biological activities, possibly as selectin inhibitors."
2014,https://doi.org/10.1002/ejoc.201402191,carbohydrate mimetics.,Septanosides,Azidooxepanes,Azidooxepanes serve as intermediates in the synthesis of various carbohydrate mimetics through copper-catalyzed [3+2] cycloadditions with alkynes,"Potential applications in drug discovery and development of new therapeutics for inflammatory conditions and vascular diseases. The resulting triazole-containing compounds may exhibit biological activities similar to carbohydrates, possibly as enzyme inhibitors or receptor ligands."
2014,https://doi.org/10.1002/ejoc.201402191,carbohydrate mimetics.,Septanosides,Triazole derivatives,"Triazole derivatives can serve as potential inhibitors in biological processes, particularly in relation to selectin interactions.","They exhibit high binding affinities towards L- and P-selectins, which are important in cell adhesion processes"
2014,https://doi.org/10.1002/ejoc.201402191,carbohydrate mimetics.,Septanosides,Divalent oxepane,"The divalent structure, along with its long flexible spacer and terminal aryl groups, shows resemblance to known selectin inhibitors, such as Bimosiamose, which have been developed for clinical studies","They exhibit high binding affinities towards L- and P-selectins, which are important in cell adhesion processes"
2014,https://link.springer.com/chapter/10.1007/7355_2014_50,Iminosugar,glucose mimetic based on its scaffold,deoxynojirimycin,Modulates the action of enzymes involved in carbohydrate synthesis and metabolism.,Demonstrated activity in inhibiting glucocerebrosidase and has been associated with therapeutic applications for lysosomal storage diseases
2014,https://link.springer.com/chapter/10.1007/7355_2014_50,Iminosugar,mannose,swainsonine,"Modulates the action of enzymes involved in carbohydrate synthesis and metabolism, specifically as an inhibitor of α-mannosidase.","1. Potential anti-cancer agent: Inhibits tumor cell growth, reduces metastasis, and enhances cellular immune responses"
2014,https://link.springer.com/chapter/10.1007/7355_2014_50,Iminosugar,glucose,castanospermine,"Modulates the action of enzymes involved in carbohydrate synthesis and metabolism, specifically as an inhibitor of glucosidases","Demonstrated activity in inhibiting glucosidases, which is relevant for therapeutic applications in lysosomal storage diseases"
2014,https://link.springer.com/chapter/10.1007/7355_2014_50,Iminosugar,glucose,nojirimycin,Modulates the action of enzymes involved in carbohydrate synthesis and metabolism,"Potential treatment for viral infections (HIV, influenza), diabetes, and cancer by inhibiting specific glycosidases"
2014,https://link.springer.com/chapter/10.1007/7355_2014_50,Iminosugar,glucose,isofagomine,"act as a pharmacological chaperone for the glucocerebrosidase enzyme, which is relevant for the treatment of Gaucher’s disease","Potential treatment for Gaucher's disease by stabilizing mutant glucocerebrosidase, enhancing its trafficking to lysosomes, and increasing its enzymatic activity"
2014,https://link.springer.com/chapter/10.1007/7355_2014_50,Iminosugar,glucose,miglitol,"Miglitol is used for the treatment of Type II diabetes and functions by inhibiting carbohydrate-processing enzymes, which helps to regulate blood sugar levels","Inhibits alpha-glucosidase enzymes, delaying carbohydrate digestion and reducing postprandial hyperglycemia"
2014,https://link.springer.com/chapter/10.1007/7355_2014_50,Iminosugar,glucose,miglustat,"It functions by inhibiting glucosylceramide synthase, which helps to reduce the accumulation of glucosylceramide in lysosomes","Miglustat is used for the treatment of lysosomal storage diseases, specifically Gaucher’s disease and Niemann Pick type C disease."
2014,https://link.springer.com/chapter/10.1007/7355_2014_50,Iminosugar,mannose,nojirimycin B,Modulates the action of enzymes involved in carbohydrate synthesis and metabolism.,Potential antiviral and antitumor agent by interfering with N-linked glycosylation
2014,https://link.springer.com/chapter/10.1007/7355_2014_50,Iminosugar,galactose,galactostatin,Inhibitor of β-galactosidase.,Potential treatment for GM1-gangliosidosis and Morquio B disease by acting as a pharmacological chaperone for lysosomal β-galactosidase
2014,https://link.springer.com/chapter/10.1007/7355_2014_50,Iminosugar,glucose,moranoline,Modulates the action of enzymes involved in carbohydrate synthesis and metabolism.,"Potential treatment for diabetes by inhibiting intestinal α-glucosidases, reducing postprandial glucose levels"
2014,https://link.springer.com/chapter/10.1007/7355_2014_50,Iminosugar,glucose,fagomine,Modulates the action of enzymes involved in carbohydrate synthesis and metabolism.,"Lowers postprandial blood glucose and modulates bacterial adhesion, potential for diabetes management and gut health"
2014,https://link.springer.com/chapter/10.1007/7355_2014_50,Iminosugar,pyranose sugars,Alexines,Modulates the action of enzymes involved in carbohydrate synthesis and metabolism.,Potential treatment for lysosomal storage disorders and as antiviral agents by inhibiting ER α-glucosidases
2014,https://link.springer.com/chapter/10.1007/7355_2014_50,Iminosugar,D-galactose,Casuarine,"inhibits glycosidases, specifically targeting enzymes like α-galactosidase.",Potential treatment for Fabry disease and other lysosomal storage disorders by inhibiting α-galactosidase
2014,https://doi.org/10.1517/17425247.2014.902048,Glycopolymers,"Naturally occurring polysaccharides (e.g., glycosaminoglycans, chondroitin sulfate)",Glycopolymers,"Anticoagulant, anti-inflammatory, anti-tumor properties","Potential applications in treating cardiovascular diseases, inflammatory conditions, and cancer by mimicking biological activities of natural polysaccharides. May also be used as drug delivery systems and protein stabilizers in pharmaceutical formulations."
2014,https://doi.org/10.1517/17425247.2014.902048,Glyconanoparticles,Glycans in lipid rafts,Glyconanoparticles (GNPs),"Targeted drug delivery, gene therapy, vaccine development","Engages in carbohydrate-protein and carbohydrate-carbohydrate interactions, shows promise for clinical applications"
2014,https://doi.org/10.4161/hv.34300,Carbohydrate Mimetic Peptide (CMP),Lewis Y (LeY) carbohydrate antigens,P10s,Induces anti-tumor antibody response and is hypothesized to interfere with cellular pathways involved in tumor cell survival.,"The P10s vaccine resulted in responses to P10s, with serum and plasma antibodies that were reactive with and cytotoxic to human breast cancer cells in vitro, including a Trastuzumab-resistant cell line. It also suggested sensitization of tumor cells for more efficient killing upon administration of chemotherapy (docetaxel)"
2014,https://doi.org/10.1021/ol500848q,Acyclic form derivatives,Acyclic intermediate of UDP-Gal f,UDP-galactitols (specifically molecules 8 and 9),Designed to mimic the acyclic form of galactitol to inhibit UGM.,"Potential antimycobacterial agent by inhibiting UGM, which is essential for mycobacterial cell envelope biosynthesis. May be effective against pathogens like Mycobacterium tuberculosis and drug-resistant Corynebacterium diphtheriae"
2014,https://doi.org/10.1021/ol500848q,C-glycosidic analogue,UDP-galactofuranose,UDP-C-Galf (20),Used for comparison in inhibition studies against UGM,"Potential antimycobacterial agent, but less effective than UDP-carbasugar 7 in inhibiting UGM, which is essential for mycobacterial cell wall biosynthesis. May have limited efficacy in treating tuberculosis and related infections due to weaker affinity for UGM"
2014,https://doi.org/10.1021/ol500848q,Transition-state analogue,Mimics high-energy intermediates of the UGM-catalyzed reaction,UDP-carbasugar (7),Designed to act as a high-energy intermediate analogue for UGM inhibition.,"Potential antimycobacterial agent by inhibiting UGM, which is essential for mycobacterial cell wall biosynthesis, particularly in treating tuberculosis and related infections"
2014,https://doi.org/10.1517/13543776.2014.916280,Amino Carbasugar,D-Glucose,Valienamine,Glycosidase inhibitor,"Inhibits α-glucosidases and is the active pharmacophore in acarbose, used to treat type 2 diabetes"
2014,https://doi.org/10.1517/13543776.2014.916280,Amino Carbasugar,D-Glucose,Acarbose,α-Glucosidase inhibitor,Used as an anti-diabetic drug to slow carbohydrate absorption in the intestine
2014,https://doi.org/10.1517/13543776.2014.916280,Iminosugar,D-Mannose,Mannojirimycin,"Inhibits α-mannosidases, which can affect glycoprotein processing.",. Potential antiviral agent against HIV and other viruses by interfering with N-linked glycosylation. May also have applications in treating lysosomal storage disorders and as an anti-inflammatory agent in cystic fibrosis.
2014,https://doi.org/10.1517/13543776.2014.916280,Thiosugar,D-Mannose,5-thio-D-mannose (Thiosugar),Glycosidase inhibitor,"Inhibits glycosidases, potentially affecting carbohydrate metabolism"
2014,https://doi.org/10.1517/13543776.2014.916280,Iminosugar,D-Mannitol,"2,5-Dideoxy-2,5-imino-D-mannitol (DMDP)",Glycosidase inhibitor,"Potential antiviral (HIV, influenza), antituberculosis, and antidiabetic agent. May also have applications in treating Gaucher's disease and as an insect antifeedant"
2014,https://doi.org/10.1517/13543776.2014.916280,Iminosugar,D-Galactose,Migalastat (Amigal),Pharmacological chaperone,"Used in the treatment of Fabry disease, Migalastat stabilizes the mutant form of the enzyme α-galactosidase A, enhancing its activity and helping to reduce substrate accumulation"
2014,https://doi.org/10.1517/13543776.2014.916280,Bicyclic Iminosugar,D-Glucose,Australine,Glycosidase inhibitor,"Isolated from Castanospermum australe, Australine has shown glycosidase inhibitory activity and potential antiviral properties"
2014,https://doi.org/10.1021/jo402574h,Bicyclic hybrid,Monosaccharide,Bicyclic diazasugar (9),Glycosidase inhibitor,"Potential treatment for metabolic disorders, viral infections, and cancer by inhibiting specific glycosidases involved in carbohydrate processing. May also have applications in treating lysosomal storage disorders by acting as a pharmacological chaperone"
2014,https://doi.org/10.1021/jo402574h,Hybrid molecule,Resembles sugars,Sugar−piperidine hybrid (5),Glycosidase inhibitor,Potential treatment for Gaucher disease and other lysosomal storage disorders by selectively inhibiting β-glucosidase (IC50 = 38.8 μM). May act as a pharmacological chaperone to stabilize mutant glucocerebrosidase enzymes and improve their trafficking to lysosomes.
2014,https://doi.org/10.1021/jo402574h,Hybrid molecule,Resembles sugars,Sugar−pyran derivative (25a),Glycosidase inhibitor,Potential treatment for GM1 gangliosidosis and related lysosomal storage disorders by inhibiting β-galactosidase (IC50 = 36.5 μM). May act as a pharmacological chaperone to stabilize mutant enzymes and improve their trafficking to lysosomes.
2014,https://doi.org/10.1021/jo402574h,Hybrid molecule,Resembles sugars,Sugar−piperidine derivative (20a),Glycosidase inhibitor,Potential treatment for Gaucher disease and other lysosomal storage disorders by selectively inhibiting β-glucosidase (IC50 = 38.8 μM). May act as a pharmacological chaperone to stabilize mutant glucocerebrosidase enzymes and improve their trafficking to lysosomes.
2015,https://doi.org/10.3762/bjoc.11.72,Divalent carbohydrate mimetics,Based on aminopyran and serinol,Divalent carbohydrate mimetics connected to carboxylic acid cores by amide bonds derived from aminopyran and serinol,"These mimetics are designed to act as inhibitors of selectins, which are crucial in the inflammatory process.","The divalent amide showed surprisingly good activities with IC50 values in the micromolar range, indicating potential effectiveness as L-selectin inhibitors for treating inflammatory conditions"
2015,https://doi.org/10.3762/bjoc.11.72,Trivalent carbohydrate mimetics,Based on aminopyran and serinol,Trivalent carbohydrate mimetics connected to carboxylic acid cores by amide bonds derived from aminopyran and serinol,"These mimetics are designed to act as inhibitors of selectins, which are crucial in the inflammatory process.",Micromolar IC50 values suggest potential as L-selectin inhibitors for treating inflammatory conditions
2015,https://doi.org/10.1002/ejoc.201403186,C-Glycosides,D-talose,Aryl C-glycosides,"Enhanced stability against enzymatic degradation
Improved oral bioavailability","Potential anticancer, antioxidant, antiviral, and hypoglycemic effects; May act as enzyme inhibitors for various diseases"
2015,https://doi.org/10.1002/ejoc.201403186,C-Glycosides,D-talose.,"Bicyclic 1,2-oxazines","Enhanced stability against enzymatic degradation
Improved oral bioavailability","Potential anticancer, antioxidant, antiviral, and hypoglycemic effects; May act as enzyme inhibitors for various diseases"
2015,https://doi.org/10.1002/ejoc.201403186,Aminopyrans,Sialyl Lewis X,O-sulfated aminopyrans,Mimic carbohydrate structures involved in cell adhesion,"Extremely high binding affinities towards L- and P-selectin, with potential applications in treating chronic inflammation (e.g., asthma)"
2015,https://doi.org/10.1002/ejoc.201403186,Sialyl Lewis X Analogs,Sialyl Lewis X,Synthetic analogs of sialyl Lewis X,Inhibit selectin-mediated cell adhesion,Potential therapeutic agents for inflammatory diseases
2015,http://dx.doi.org/10.1055/s-0034-1380201., N-alkylated compounds,Pyranose,"Secondary amine 9, obtained from the reaction of aminopyran with pentanal",Potential glycosidase inhibitor,May help in managing metabolic disorders like diabetes by regulating carbohydrate digestion
2015,http://dx.doi.org/10.1055/s-0034-1380201., N-alkylated compounds,Pyranose,"Secondary amine 10, obtained from the reaction of aminopyran with benzaldehyde",Potential glycosidase inhibitor,May help in managing metabolic disorders like diabetes by regulating carbohydrate digestion
2015,http://dx.doi.org/10.1055/s-0034-1380201., N-alkylated compounds,Pyranose,"Secondary amine 11, obtained from the reaction of aminopyran with 4-bromobenzaldehyde",Potential glycosidase inhibitor,May help in managing metabolic disorders like diabetes by regulating carbohydrate digestion
2015,https://doi.org/10.1002/chem.201500831,Carbohydrate mimetic,Neuraminic acid,Zanamivir (Relenza),Targets influenza viral neuraminidase,Antiviral activity against influenza viruses
2015,https://doi.org/10.1002/chem.201500831, Carbohydrate mimetic,Neuraminic acid,Oseltamivir (Tamiflu),Targets influenza viral neuraminidase,Antiviral activity against influenza viruses
2015,https://doi.org/10.1002/chem.201500831,Glycolipid mimic,a-GalCer,Synthetic C-glycoside analogues of a-GalCer glycolipid,Stimulates human NKT cells,activity in malaria and melanoma models
2015,https://doi.org/10.1002/bmb.20915,Dimeric Aminoglycosides,natural carbohydrates,Dimeric Aminoglycosides,"The primary function of these dimeric aminoglycosides is to inhibit the interaction between the HIV Trans-activator of transcription (Tat) protein and the Trans Activation Responsive (TAR) RNA. This interaction is crucial for the activation of transcription in the HIV life cycle, making it a valuable target for therapeutic intervention.","The activity of these carbohydrate-based dimeric target molecules lies in their ability to block the Tat-TAR interaction, thereby exerting antiviral effects. The inhibition of this interaction can potentially prevent the replication of the virus, contributing to therapeutic strategies against HIV."
2015,https://doi.org/10.1016/j.toxicon.2015.08.003,Carbohydrate receptor mimic,Galactose-containing carbohydrates,Lactulose (LAU),"Inhibits the oral toxicity of botulinum neurotoxin A (BoNT/A) by binding to the HA complex, preventing it from compromising the integrity of epithelial cell monolayers and blocking internalization.",Demonstrated protective effects against BoNT/A oral intoxication in vivo
2015,https://doi.org/10.1016/j.toxicon.2015.08.003,Non-metabolizable Gal analog,Galactose,Iso-propyl β-D-1-thiogalactopyranoside (IPTG),Inhibits the oral toxicity of BoNT/A by competing with endogenous carbohydrate receptors on the cell surface,Significantly extended the median survival time of mice in oral intoxication models
2015,https://doi.org/10.1016/j.copbio.2014.11.016,Synthetic Lectin,Glucose and its epimers,Boronic Acid-Based Receptors,These receptors utilize boronate ester formation to bind carbohydrates.,Potential applications in diabetes monitoring and management through selective glucose sensing. May also have uses in developing targeted drug delivery systems or diagnostic tools for diseases involving altered glucose levels or metabolism.
2015,https://doi.org/10.1016/j.copbio.2014.11.016,Synthetic Receptor,Equatorial glucosides,Tripodal Benzene Receptors,Designed to bind equatorial glucosides using noncovalent interactions.,Exploitable for targeted drug delivery and carbohydrate sensing
2015,https://doi.org/10.1016/j.copbio.2014.11.016,Synthetic Receptor,All-equatorial carbohydrates,Temple Receptors,These receptors are structured to bind carbohydrates effectively using a combination of hydrophobic and polar interactions.,"Potential for targeted drug delivery, cellular imaging, or carbohydrate-based therapeutics for diseases"
2015,https://doi.org/10.1016/j.copbio.2014.11.016,Synthetic Receptor,Beta-mannosides,Pyrrolic Tripodal Receptor,Specifically recognizes beta-mannosides.,"Potential for targeted drug delivery, biosensing, and diagnostic applications related to mannoside-mediated processes. May be used to target cancer cells that overexpress mannose receptors or to modulate immune responses."
2015,https://doi.org/10.1021/acs.orglett.5b02223,S-linked hexasaccharide,Hexasaccharide subunit of landomycin A,S-linked hexasaccharide of landomycin A,Designed to be resistant to acid-mediated or enzymatic hydrolysis,"The mimetic is associated with antitumor activity against cancer cell lines, as landomycin A possesses a broad spectrum of antitumor activity"
2015,http://dx.doi.org/10.1517/17460441.2015.1067198,Adjuvant,"Trehalose-6,6'-dibehenate (TDB)",Trehalose,Adjuvant in vaccine formulations.,"Enhances immune responses, particularly in tuberculosis vaccines."
2015,https://doi.org/10.1002/chem.201500831,Glycomimetic drug,Sialyl Lewis x (sLe^x),GMI-1070 (Rivipansel),Potent pan-selectin antagonist,Reverses vaso-occlusion in sickle cell disease and is in clinical trials for this condition
2015,https://doi.org/10.1002/chem.201500831,Glycomimetic drug,Sialyl Lewis x (sLe^x),GMI-1271,Specific E-selectin inhibitor,Evaluated in clinical trials in combination with chemotherapy for treating acute myeloid leukemia
2015,https://doi.org/10.1002/chem.201500831,Synthetic carbohydrate mimic,2G12 epitope,Unnatural oligomannose mimics,Targeting high-mannose epitopes for immune response,aimed at improving immune response against HIV.
2015,https://doi.org/10.1002/chem.201500831,Glycomimetic compound,Sialic acid,High-affinity sialic acid mimetics,Inhibitor of myelin-associated glycoprotein (MAG),Promotes neurite outgrowth; potential therapeutic applications in neuronal repair and spinal cord injury.
2015,https://doi.org/10.1002/chem.201500831,Synthetic glycoprotein mimic,Glycan structures found on PSGL-1,Synthetic P-selectin–glycoprotein–ligand-1 (PSGL-1) mimics,Diagnostic probe for in vivo inflammatory brain damage,Used for detection of early P-selectin expression in inflammatory brain lesions and cerebral malaria pathology in mice.
2015,https://doi.org/10.1002/chem.201500831,Glycan-based therapeutic,Various carbohydrate structures (often mimicking natural glycan epitopes),Multivalent Glycoconjugates,Designed to enhance affinity for protein targets by mimicking the multivalent nature of interactions between lectins and their natural carbohydrate ligands,"Developed to improve the overall affinity of glycan therapeutics, with examples including glycodendrimers and glycoclusters."
2016,https://doi.org/10.1021/acs.joc.6b00302,Fluorinated Carbohydrate Mimic,D-threo-hexopyranose,"2,3-dideoxy -2,2,3,3-tetrafluoro D -thereo hexopyranose",Potential inhibitor of carbohydrate-processing enzymes,"May have therapeutic potential in treating diseases involving carbohydrate metabolism, such as diabetes or viral infections"
2016,https://doi.org/10.1021/acs.joc.6b00302,Fluorinated Carbohydrate Mimic,D-threo-hexofuranose,"2,3-dideoxy -2,2,3,3-tetrafluoro D -thereo hexofuranose",Potential inhibitor of carbohydrate-processing enzymes,"May have therapeutic potential in treating diseases involving carbohydrate metabolism, such as diabetes or viral infections"
2016,https://doi.org/10.1021/acs.joc.6b00302,Fluorinated Carbohydrate Mimic,D-erythro-hexopyranose,"2,3-dideoxy -2,2,3,3-tetrafluoro D -erythro hexopyranose",Potential inhibitor of carbohydrate-processing enzymes,"May have therapeutic potential in treating diseases involving carbohydrate metabolism, such as diabetes or viral infections"
2016,https://doi.org/10.1021/acs.joc.6b00302,Fluorinated Carbohydrate Mimic,D-threo-hexopyranose,"3,4-dideoxy -3,3,4,4-tetrafluoro D -threo hexopyranose",Potential inhibitor of carbohydrate-processing enzymes,"May have therapeutic potential in treating diseases involving carbohydrate metabolism, such as diabetes or viral infections"
2016,https://doi.org/10.1021/acs.joc.6b00302,Fluorinated Carbohydrate Mimic,D-erythro-hexopyranose,"3,4-dideoxy -3,3,4,4-tetrafluoro D -erythro hexopyranose",Potential inhibitor of carbohydrate-processing enzymes,"May have therapeutic potential in treating diseases involving carbohydrate metabolism, such as diabetes or viral infections"
2016,https://doi.org/10.1021/acs.joc.6b00302,Fluorinated Nucleotide Sugar Mimetics,UDP-Galactose (UDP-Gal),dideoxy-tetrafluorinated uridine diphosphate (UDP)-Gal analogues,Inhibitor of the enzyme UDP-galactopyranose mutase (UGM),Potential antimycobacterial agent with improved activity against tuberculosis
2016,DOI: 10.1016/j.tibtech.2016.01.004,Fucose-based glycomimetic,Lewis X oligosaccharide,α-fucosyl-β-alanyl amide,Targets DC-SIGN without inducing dendritic cell maturation and IL-10 production,"Acts as a potent DC-SIGN targeting device, suggesting potential use in targeted imaging or antigen delivery"
2016,DOI: 10.1016/j.tibtech.2016.01.004,Mannose-based glycomimetic,"1,2-mannobioside and linear Man-α-1,2-Man-α-1,6-Man trisaccharide",Mannose-based glycomimetic antagonists,Antagonists of protein-sugar interactions,Effective in hampering microbial adhesion
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Non-natural sugar,N-acetylglucosamine,GlcNAz (N-acetylglucosamine azide),Metabolically incorporated into cells for labeling and detection.,Used in glycobiology research to study glycosylation processes in cancer and immune responses
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Non-natural sugar,N-acetylmannosamine,ManNAz (N-acetylmannosamine azide),Metabolically incorporated into cells.,Used in glycobiology research to study glycosylation processes in cancer and immune responses
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Non-natural sugar,N-acetylgalactosamine,GalNAz (N-acetylgalactosamine azide),Metabolically incorporated into cells.,Facilitates the labeling of glycoproteins and tracking of glycosylation
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Non-natural sugar,N-acetylmannosamine,ManNAl (N-acetylmannosamine alkyne),Used for metabolic incorporation and subsequent 'click' reactions.,Allows for the study of cell surface glycans and their role in diseases
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Non-natural sugar,N-acetylmannosamine,ManNCyoc (N-acetylmannosamine cyano),Metabolically incorporated into cells.,"Used in studies of glycosylation and cellular interactions, impacting diseases processes"
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Non-natural sugar,N-acetylmannosamine,ManNMCp (N-acetylmannosamine methylcyclopropene),Metabolically incorporated into cells.,Facilitates the study of glycosylation patterns
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Non-natural sugar,N-acetylmannosamine,ManNCp (N-acetylmannosamine cyclopropene),Used for metabolic incorporation.,Allows for the tracking of modified glycans in the context of cancer and other diseases
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Non-natural sugar,Sialic acid,BCNSia (a specific sialic acid mimic),Used in studies of glycosylation.,Helps in understanding the role of sialylation in cellular processes related to cancer and immune responses
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Nucleotide sugar,Xylose,UDP-4-XylAz (uridine diphosphate 4-xylose azide),Used for metabolic incorporation into glycan structures.,Facilitates the study of glycan biosynthesis
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Non-natural sugar,Glucosamine,GlcN-n-Iso ,Used for metabolic incorporation into cellular processes.,"it can be utilized in studies related to glycosylation and may serve as a tool for investigating glycan interactions and modifications in biological systems, particularly within cancer cells."
2016,https://doi.org/10.1021/acs.joc.6b01876,Carbasugar,α-Galactose,(−)-MK7607,Potent herbicidal activity,"Isolated from the cultures of Curvularia eragrostidis D2452, it has considerable interest due to its herbicidal properties"
2016,https://doi.org/10.1021/acs.joc.6b01876,Carbasugar,Cyclitol,(−)-Epoxydine B,Glycosidase inhibitor,"Exhibits antibacterial, antifungal, and antialgal  activities; potential for treating infections"
2016,https://doi.org/10.1021/acs.joc.6b01876,Carbasugar,Cyclitol,(−)-Epoxydine C,Glycosidase inhibitor,"Exhibits antibacterial, antifungal, and antialgal  activities; potential for treating infections"
2017,https://doi.org/10.1021/acscentsci.7b00214,irreversible glycosidase inhibitors,α-glucosidase,"1,6-Epi-Cyclophellitol Cyclosulfate (α-cyclosulfate)","Cyclophellitol cyclosulfates are designed to mimic the carbohydrate substrate of α-glucosidases, acting as inhibitors of these enzymes",Potent nanomolar α-glucosidase inhibitor with potential therapeutic applications in treating lysosomal storage disorders and other diseases involving α-glucosidase activity
2017,https://doi.org/10.1021/acscentsci.7b00214,irreversible glycosidase inhibitors,α-glucosidase,"1,6-Cyclophellitol Cyclosulfate (β-cyclosulfate)","Cyclophellitol cyclosulfates are designed to mimic the carbohydrate substrate of α-glucosidases, acting as inhibitors of these enzymes","Modest inhibitor of β-glucosidases with potential applications in treating Gaucher disease and other lysosomal storage disorders, albeit less effective than α-cyclosulfate"
2017,https://doi.org/10.1021/acscentsci.7b00214,β-glucosidase inhibitors.,"β-Glucose substrates in their transition state, specifically the 4H3 conformation adopted by retaining β-glucosidase substrates.",Cyclophellitol Aziridine,"Mimics the transition state of β-glucose substrates to bind and inhibit β-glucosidases. Forms a covalent adduct with the enzyme, leading to permanent inhibition through nucleophilic attack and ring opening.","Potential treatment for lysosomal storage disorders, particularly Gaucher disease, by inhibiting glucocerebrosidase (GBA1) and non-lysosomal glucosylceramidase (GBA2)"
2017,https://doi.org/10.1002/chem.201703129,"five-membered heterocycles containing one double bond, 
one oxygen and one phosphorus atom",Furanose carbohydrate,"Oxaphospholenes 
3-4",serve as precursors for furanose carbohydrate mimics,Potential applications in developing anti-cancer and anti-diabetic drugs by mimicking furanose-based enzyme substrates or inhibitors
2017,https://doi.org/10.1039/C7OB00386B,Glycolipid mimetics,Monosaccharides,Penaresidins,"Actomyosin ATPase activator, potential biomarker","Cytotoxicity against cancer cell lines, potential biomarker for cervical cancer, antimicrobial activity against Mycobacterium tuberculosis"
2017,https://doi.org/10.1039/C7OB00386B,Glycolipid mimetics,Monosaccharides,Penazetidine A,Protein kinase C inhibitor,"Cytotoxicity against human and murine cell lines (A549, HT-29, B16/F10, P388), potential anticancer activity"
2017,https://doi.org/10.1039/C7OB00386B,Nucleoside analogue,guanosine,Oxetanocin A,Inhibits viral DNA polymerases and reverse transcriptases,"Potent antiviral activity against HIV, HSV-1, HSV-2, and HCMV; potential antitumor and antibacterial properties"
2017,https://doi.org/10.1039/C7OB00386B,Glycoside analogue,Monosaccharides,Oxetanosides,Related to the synthesis of oxetanocin A and its analogues.,"Potential antiviral, antitumor, and antibacterial activities"
2017,https://doi.org/10.1039/C7OB00386B,Nitrogen-containing square sugars,Monosaccharides,Azetidine-based sugars,"Designed as constrained analogues of iminosugars, which are a major class of carbohydrate mimics.","Some azetidine derivatives have shown biological activities, including inhibition of enzymes like E. coli β-glucuronidase"
2017,https://doi.org/10.1039/C7OB00386B,Azetidine-based sugar,Monosaccharides,Azetidinol,Inhibits β-N-acetylhexosaminidases,Potential treatment for lysosomal storage disorders like Tay-Sachs disease
2017,https://doi.org/10.1039/C7OB00386B,Azetidine derivative,Monosaccharides,Bicyclic azetidine,Amyloglucosidase inhibitor,Potential treatment for diabetes by regulating carbohydrate digestion
2017,https://doi.org/10.1039/C7OB00386B,Thietanose analogue,furanose sugars,Thietanose,Designed as a carbohydrate mimic with potential applications in organic chemistry.,Potential anti-HIV activity
2017,https://doi.org/10.1039/C7OB00386B,Thiethane analogue,furanose sugars,Pseudothietanose,Related to the synthesis of thietanose analogues.,Potential anti-HIV activity
2017,https://doi.org/10.1039/C7OB00386B,Cyclobutane derivatives,Monosaccharides,Highly-functionalized cyclobutanes,Explored for their potential in medicinal chemistry.,"May improve drug properties such as metabolic stability and conformational restriction, with potential applications in various diseases including cancer, viral infections, and neurodegenerative disorders"
2017,https://doi.org/10.1080/1040841X.2016.1242868,Iminosugar,Deoxynojirimycin (DNJ),"N-butyl-deoxynojirimycin (N B-DNJ, Miglustat)",Inhibitor of glycosphingolipid biosynthesis and glucosidases,"Used in the treatment of type I Gaucher disease and Niemann-Pick type C disease; has demonstrated antiviral activity against various viruses, including HIV-1 and DENV"
2017,https://doi.org/10.1080/1040841X.2016.1242868,Iminosugar,Deoxynojirimycin (DNJ),N-hydroxyethyldeoxynojirimycin (Miglitol),Inhibitor of glucosidases,Used in the treatment of non-insulin-dependent diabetes
2017,https://doi.org/10.1080/1040841X.2016.1242868,Iminosugar,Castanospermine,6-O-butanoyl castanospermine (BuCAST),Inhibitor of glycosphingolipid biosynthesis and glucosidases,Reduced murine brain viral load of herpes simplex virus type 1 (HSV-1) following cutaneous infection; tested in vivo against a range of influenza virus strains with reduced pathology and increased survival in murine lethal infection models
2017,https://doi.org/10.1080/1040841X.2016.1242868,Iminosugar,Sialic acid,3-episiastatin B,Neuraminidase inhibitor,Potent inhibitory activities against influenza virus neuraminidases and influenza virus infection
2017,https://doi.org/10.1080/1040841X.2016.1242868,Iminosugar,Deoxynojirimycin (DNJ),N-nonyl-deoxynojirimycin (N N-DNJ),Inhibitor of glycosphingolipid biosynthesis and glucosidases,Reduced secretion of glycoproteins E and NS1 and virion production in dengue virus (DENV) and Japanese encephalitis virus (JEV); reduced mortality rate in a JEV mouse lethal challenge model
2017,https://doi.org/10.1080/1040841X.2016.1242868,Iminosugar,Deoxynojirimycin (DNJ),N-(9-methoxynonyl)-1-deoxynojirimycin (M O N-DNJ),Inhibitor of glycosphingolipid biosynthesis and glucosidases,Demonstrated protective effects against lethal doses of H1N1 influenza viruses and reduced mortality rate in a mouse lethal challenge model
2017,https://doi.org/10.1016/j.carres.2017.03.012,Inositol Mimic,L-rhamnopyranose,D-pinitol,Potential sugar substitute,Potential applications in diabetes management due to its insulin-like effects and in treating polycystic ovary syndrome
2017,https://doi.org/10.1016/j.carres.2017.03.012,Azasugars,Various sugars,Azasugars,Inhibition of glycosidases,Used in treatments for type 1 Gaucher disease (Zavesca®) and type II diabetes (Glyset)
2017,https://doi.org/10.1016/j.carres.2017.03.012,Carbasugars,Various sugars,Carbasugars,"Enhanced biostability and inhibition of specific enzymes (e.g., Ser/Thr protein kinase, SGLT2, heparanase)","Potential treatments for cancer, diabetes, and inflammatory diseases due to their increased chemical stability and specific enzyme inhibition"
2017,https://doi.org/10.1016/j.carres.2017.03.012,Inositol Mimic,Rhamnopyranoside residue of a trisaccharide,Inositol Analogues,Potential use in synthetic vaccines,"May lead to more effective and stable vaccines against bacterial infections, particularly those with capsular polysaccharides"
2017,https://doi.org/10.1021/acs.orglett.7b00945,Cyclitol analogue,Rhamnose,2a (n-Pr cyclitol diacetate),Designed to improve bioavailability and inhibit RSK1/2 activity.,"Potential anticancer agent due to improved RSK inhibition, which may suppress tumor growth and metastasis"
2017,https://doi.org/10.1021/acs.orglett.7b00945,Cyclitol analogue,Rhamnose,2b (C-3/C-4 bis-carbamate),Aimed at enhancing stability and RSK inhibition.,"Promising anticancer activity through RSK inhibition, potentially effective in treating various types of cancer"
2017,https://doi.org/10.1021/acs.orglett.7b00945,Carbasugar analogue,"Sugars in general, particularly rhamnose derivatives.",5a-carbasugar analogues,To explore structure-activity relationships and improve RSK1/2 inhibition.,Part of ongoing research to develop more effective anticancer treatments targeting RSK-mediated pathways
2017,https://doi.org/10.1021/acs.orglett.7b00945,Structural modification,Rhamnose (specifically the C-3 and C-4 positions),C-3/C-4-n-Pr-carbamates,To enhance the stability and efficacy of the analogues.,Potential improvement in anticancer activity through more stable and effective RSK inhibition
2017,http://doi.org/10.1371/journal.pone.0185653,Not Specified Explicitly,Insulin,Egg White Hydrolysate (EWH),"EWH exhibits both insulin mimetic and sensitizing effects, particularly in adipocytes (fat cells).","It enhances phosphorylation of ERK1/2 and Akt, which are crucial for insulin signaling pathways, promoting glucose transport and adipocyte differentiation"
2017,http://doi.org/10.1371/journal.pone.0185653,Not Specified Explicitly,Insulin,Milk-Derived Peptides (IPP and VPP),: These peptides have ACE-inhibitory and anti-inflammatory properties.,"They promote the differentiation of pre-adipocytes, similar to insulin's effects on adipose tissue"
2017,http://doi.org/10.1371/journal.pone.0185653,Not Specified Explicitly,Angiotensin II,Captopril (ACE Inhibitor),Primarily used for hypertension management.,Primarily used for hypertension management.
2017,http://doi.org/10.1371/journal.pone.0185653,Not Specified Explicitly,Insulin,Flaxseed Protein Hydrolysate,Function: Contains peptide fractions with anti-hypertensive and anti-diabetic properties.,Promotes insulin-like effects in glucose metabolism and adipocyte function
2017,http://doi.org/10.1371/journal.pone.0185653,Not Specified Explicitly,Insulin,Synthetic Insulin Mimetics,Designed to activate insulin receptors.,"They aim to replicate insulin's effects on glucose uptake and metabolism, potentially useful in diabetes management."
2017,http://doi.org/10.1371/journal.pone.0185653,Not Specified Explicitly,Glucagon-like peptide-1 (GLP-1),GLP-1 analogs,Enhances insulin secretion in response to meals.,These mimetics improve glycemic control and promote weight loss in type 2 diabetes patients.
2018,https://doi.org/10.3390/antiox7110156,Therapeutic agents,Superoxide Dismutases,Superoxide Dismutases Mimetics MnSOD,"enhance the body's natural defense against oxidative stress, particularly in conditions where SOD levels are insufficient or dysregulated.","exhibit superoxide scavenging activity, helping to protect cells from oxidative damage."
2018,https://doi.org/10.3390/ijms21197349,Amphipathic peptide,Apolipoprotein A-I (apoA-I),Neutral (neu),Promotes cholesterol efflux by interacting with the ABCA1 transporter,Forms a stable HDL-like scaffold and stabilizes nanodiscs during cholesterol efflux.
2018,https://doi.org/10.3390/ijms21197349,Amphipathic peptide,Apolipoprotein A-I (apoA-I),Hydrophobic (hyd),Enhances cholesterol efflux through its larger hydrophobic face.,"Exhibits high helicity and forms oligomers, which may stabilize HDL-like particles."
2018,https://doi.org/10.3390/ijms21197349,Amphipathic peptide,Apolipoprotein A-I (apoA-I),Positive (pos),"Facilitates cholesterol efflux, albeit with a smaller hydrophobic face compared to neu.","Has a net positive charge, which may influence its interaction with membranes."
2018,https://doi.org/10.3390/ijms21197349,Amphipathic peptide,Apolipoprotein A-I (apoA-I),Negative (neg),Attempts to promote cholesterol efflux but is less effective due to charge repulsion.,"Initially dimerizes but fails to form stable oligomers, limiting its efficacy."
2018,https://doi.org/10.1136/svn-2018-000152,Anti-inflammatory peptide,Apolipoprotein E (apoE),CN-105,ApoE is involved in lipid metabolism and has neuroprotective and anti-inflammatory properties. It plays a crucial role in the central nervous system (CNS) by modulating glial activation and inflammatory responses following brain injuries.,"reduce inflammation, vasospasm, and neuronal injury in a murine model of subarachnoid hemorrhage (SAH). It is associated with improved long-term behavioral outcomes and has a favorable pharmacokinetic profile, allowing for better CNS penetration compared to the intact apoE protein, which does not readily cross the blood-brain barrier"
2018,https://doi.org/10.1177/0963689718791568,Not Specified Explicitly,Angiopoietin-1 (Ang1),Vasculotide,"angiogenic growth factor that plays a crucial role in vascular maturation and immune response. It activates the Tie-2 receptor,","mimics Ang1's activity by activating Tie-2, leading to enhanced vascularization and neuronal health. It has been shown to decrease neuroinflammation and improve functional outcomes in models of stroke, particularly in type 1 diabetic rats"
2018,https://doi.org/10.1038/s41467-017-02693-9,mimetic inhibitor.,BCL-2,ABT-199 (Venetoclax),"Inhibits the anti-apoptotic function of BCL-2, promoting apoptosis in cancer cells.","Selectively binds to BCL-2, preventing it from sequestering pro-apoptotic proteins."
2018,https://doi.org/10.1038/s41467-017-02693-9,mimetic inhibitor.,BCL-2 and BCL-XL,ABT-263 (Navitoclax),"Induces apoptosis by inhibiting BCL-2 and BCL-XL, which are crucial for cell survival.",Disrupts the interaction between pro-apoptotic and anti-apoptotic BCL-2 family proteins.
2018,https://doi.org/10.1038/s41467-017-02693-9,inhibitor.,MCL1,S63845,"Specifically targets and inhibits MCL1, leading to apoptosis in MCL1-dependent cancer cells.","Blocks the anti-apoptotic function of MCL1, enhancing the effectiveness of other therapies."
2018,https://doi.org/10.1038/s41467-017-02693-9,Deubiquitinase inhibitor.,USP13 (indirectly),Spautin-1,"Inhibits USP13, leading to decreased MCL1 stability and increased sensitivity to BH3 mimetics.",Promotes degradation of MCL1 through the proteasomal pathway.
2018,https://doi.org/10.1038/s41467-017-02693-9,Deubiquitinase inhibitor.,USP7,P5091,"Inhibits USP7, leading to activation of the p53 pathway, which can induce apoptosis in cancer cells.",Enhances the degradation of oncogenic proteins regulated by USP7.
2018,https://doi.org/10.1186/s12868-018-0482-4,Chemical hypoxia mimetic,Hypoxia,Cobalt Chloride (CoCl2),"CoCl2 induces chemical hypoxia by stabilizing hypoxia-inducible factor-1 alpha (HIF-1α), which is crucial for activating hypoxia response pathways.","It increases reactive oxygen species (ROS) production and causes cell death in a dose-dependent manner, leading to oxidative stress in cells."
2018,https://doi.org/10.1186/s12868-018-0482-4,Pharmacological agent,mTOR inhibition,Rapamycin,"Rapamycin is a well-known inhibitor of the mammalian target of rapamycin (mTOR), which regulates cell growth, metabolism, and survival.","It increases cell viability during CoCl2 exposure, reduces activation of caspases-9 and -3, and promotes autophagy by increasing Beclin-1 and converting LC3-I to LC3-II."
2018,https://doi.org/10.1186/s12868-018-0482-4,Not Specified Explicitly,Anti-apoptotic protein,Bcl-2 (B cell lymphoma-2),"Bcl-2 helps prevent apoptosis by inhibiting the release of cytochrome c from mitochondria, thus blocking the intrinsic apoptotic pathway.","Its expression increases with rapamycin treatment, contributing to reduced oxidative stress and promoting cell survival."
2018,https://doi.org/10.1186/s12868-018-0482-4,Not Specified Explicitly,Pro-apoptotic protein,Bax (Bcl-2 associated X protein),Bax promotes apoptosis by facilitating mitochondrial outer membrane permeability (MOMP) and triggering the release of pro-apoptotic factors.,"The expression of Bax decreases with rapamycin treatment, which helps to favor cell survival by lowering the Bax/Bcl-2 ratio."
2018,https://doi.org/10.1080/21691401.2018.1489824,Not Specified Explicitly,NK-EM,Perforin,"Perforin is crucial for the cytotoxic activity of NK cells. It forms pores in the target cell membrane, facilitating the entry of granzymes.","Triggers the intrinsic apoptotic pathway by releasing cytochrome-c from mitochondria, leading to cell death."
2018,https://doi.org/10.1080/21691401.2018.1489824,Not Specified Explicitly,NK-EM,Granzyme B,Granzyme B is a serine protease that enters target cells through the pores created by perforin and initiates apoptosis.,"Activates caspases, which are essential for the apoptotic process, leading to cell death."
2018,https://doi.org/10.1080/21691401.2018.1489824,Not Specified Explicitly,NK-EM,Fas Ligand (FasL),"FasL binds to the Fas receptor on target cells, triggering the extrinsic apoptotic pathway.","Activates caspase-8 and caspase-3, leading to apoptosis of the target cell."
2018,https://doi.org/10.1080/21691401.2018.1489824,Not Specified Explicitly,Cleaved caspase-3 in NK-EM,Caspase-3,Caspase-3 is an executioner caspase that plays a pivotal role in the apoptosis process.,"Cleaved caspase-3 indicates the activation of the apoptotic pathway, leading to cell death"
2018,https://doi.org/10.1080/21691401.2018.1489824,Not Specified Explicitly,Cleaved PARP in NK-EM,Cleaved PARP (Poly (ADP-ribose) polymerase),PARP is involved in DNA repair; its cleavage is a marker of apoptosis.,The presence of cleaved PARP indicates that the cell is undergoing apoptosis.
2018,https://doi.org/10.1101/312447,Smac mimetic,Active N-terminal tetrapeptide of SMAC,AZD5582,", it promotes apoptosis by inhibiting IAPs.",": AZD5582 has been shown to potently induce degradation of cIAP1 and cIAP2, leading to activation of the ncNFκB pathway and increased expression of HIV RNA in resting CD4+ T cells."
2018,https://doi.org/10.3389/fphar.2018.01298,Smac mimetic,SMAC (Second Mitochondria-derived Activator of Caspases),APG-1387,"APG-1387 acts as an inhibitor of apoptosis proteins (IAPs) by mimicking the binding interaction between IAPs and SMAC. This leads to the activation of caspases, which are crucial for the apoptotic process.","Induces apoptosis in hepatocellular carcinoma (HCC) cells, particularly when combined with cytokines like TNF-α or TRAIL."
2018,https://doi.org/10.1073/pnas.1714518115,Not Specified Explicitly,Desmosterol,DMHCA (Dissociated LXR Agonist),Activates LXR (Liver X Receptor) target genes while repressing SREBP (Sterol Regulatory Element-Binding Protein) target genes.,"Induces expression of LXR-responsive genes like Abca1 and represses SREBP-responsive genes such as Dhcr24 and Hmgcr in macrophages and Kupffer cells, but not in hepatocytes"
2018,https://doi.org/10.1073/pnas.1714518115,Not Specified Explicitly,Desmosterol,MePipHCA (Synthetic Desmosterol Mimetic),"Similar to DMHCA, it activates LXR target genes and suppresses SREBP target genes.","Strongly activates LXR target genes in macrophages and represses Dhcr24 expression, demonstrating a profile consistent with desmosterol mimetics"
2018,https://doi.org/10.1016/j.actbio.2018.03.034,Not Specified Explicitly,Heparin,Poly-vinylsulfonic acid (PVSA),Stabilizes BMP-2 and enhances osteogenesis,Preserves bioactivity of BMP-2 during stress exposure; binds BMP-2 more effectively than unmodified MeGC hydrogel; enhances osteogenic differentiation of encapsulated bone marrow stromal cells (BMSCs) without exogenous BMP-2 and improves delivery of exogenous BMP-2.
2018,https://doi.org/10.1016/j.actbio.2018.03.034,Not Specified Explicitly,Heparin,Poly-4-styrenesulfonic acid (PSS),Stabilizes BMP-2 and enhances osteogenesis,Preserves bioactivity of BMP-2 during stress exposure; binds BMP-2 more effectively than unmodified MeGC hydrogel; enhances osteogenic differentiation of encapsulated bone marrow stromal cells (BMSCs) without exogenous BMP-2 and improves delivery of exogenous BMP-2.
2019,https://doi.org/10.3390/ijms20235835,affinity proteins ;targeting receptors,staphylococcal protein A.,Affibody molecules,designed to target the HER2 receptor in breast cancer cells.,"have rapid clearance, high tissue penetration, and the ability to bind to a unique epitope of the HER2 receptor"
2019,http://dx.doi.org/10.2174/0929867324666171005110620,conformational mimetic,α-melanocyte-stimulating hormone (α-MSH).,caseinolytic protease B (ClpB).,"α-MSH inhibits feeding behavior through activation of melanocortin receptors (e.g., MC4R) in the hypothalamus.","It promotes thermogenesis and energy consumption, which helps maintain body weight."
2019,https://pubs.acs.org/doi/full/10.1021/acsinfecdis.9b00002,Inhibitor,autoinducing peptide,n7OFF,"functions as an AgrC antagonist, blocking the receptor and preventing the upregulation of the agr system.","inhibits quorum sensing (QS) and thereby reduces the production of virulence factors in S. aureus, which are crucial for the bacteria’s pathogenicity."
2019,https://pubs.acs.org/doi/full/10.1021/acsinfecdis.9b00002,Not Specified Explicitly,autoinducing peptide,Bnc3,potent AgrC antagonist showing low- to sub-nanomolar inhibitory activity.,"prevents the activation of QS, ultimately reducing S. aureus virulence."
2019,https://doi.org/10.1073/pnas.1819663116,peptidomimetics,B Cell Lymphoma 9 (BCL9),Helical sulfono-γ-AApeptides,disrupt the β-catenin/BCL9 protein-protein interaction (PPI) with high potency and specificity. They are designed to structurally and functionally mimic the α-helix,"They are designed to structurally and functionally mimic the α-helical HD2 domain of BCL9, effectively inhibiting cancer-related signaling pathways associated with β-catenin"
2019,https://doi.org/10.1073/pnas.1819663116,Not Specified Explicitly,B Cell Lymphoma 9 (BCL9),BCL9 peptide 1,"disrupt the β-catenin/BCL9 PPI but is less potent compared to the sulfono-γ-AApeptides, with higher K_i and IC_50 values","designed to structurally and functionally mimic the α-helical HD2 domain of BCL9, effectively inhibiting cancer-related signaling pathways associated with β-catenin"
2019,https://doi.org/10.1021/acsinfecdis.9b00002,Peptidomimetic,Autoinducing Peptides (AIPs),Bnc3,"acts as an antagonist to the AgrC receptor, inhibiting the quorum sensing (QS) system in S. aureus, which is crucial for regulating virulence factors.","exhibits low-to sub-nanomolar inhibitory activity against AgrC across all four S. aureus agr specificity groups, indicating its high potency as a QS inhibitor"
2019,https://doi.org/10.1021/acsinfecdis.9b00002,Peptidomimetic,A simplified version of AIPs,n7OFF,"serves as a peptidomimetic that also targets the AgrC receptor, contributing to the inhibition of the agr system.",enhance its potency through structural modifications
2019,https://doi.org/10.1038/s41418-019-0391-9,BCL-2/BCL-XL inhibitor,BCL-2 and BCL-XL,ABT-737,Inhibits anti-apoptotic proteins to promote apoptosis.,Validated as a true BH3 mimetic with effective mitochondrial activity.
2019,https://doi.org/10.1038/s41418-019-0391-9,BCL-2/BCL-XL inhibitor,BCL-2 and BCL-XL,ABT-263 (Navitoclax),Induces apoptosis by inhibiting anti-apoptotic proteins.,Induces apoptosis by inhibiting anti-apoptotic proteins.
2019,https://doi.org/10.1038/s41418-019-0391-9,BCL-2/BCL-XL inhibitor,BCL-2 and BCL-XL,AZD4320,Antagonizes the function of anti-apoptotic proteins.,Validated as a true BH3 mimetic with effective mitochondrial activity.
2019,https://doi.org/10.1038/s41418-019-0391-9,BCL-2 inhibitor,BCL-2,ABT-199 (Venetoclax),Selectively inhibits BCL-2 to promote apoptosis in BCL-2-dependent cells.,"Effective in low to mid-nanomolar range, validated as a BH3 mimetic."
2019,https://doi.org/10.1038/s41418-019-0391-9,BCL-XL inhibitor,BCL-XL,WEHI-539,Selectively inhibits BCL-XL to induce apoptosis.,Strong selective release of cytochrome c from BCL-XL-dependent mitochondria.
2019,https://doi.org/10.1038/s41418-019-0391-9,BCL-XL inhibitor,BCL-XL,A-1155463,Inhibits BCL-XL to promote apoptosis.,Demonstrated strong selective activity in BCL-XL-dependent cells.
2019,https://doi.org/10.1038/s41418-019-0391-9,BCL-XL inhibitor,BCL-XL,A-1331852,Antagonizes BCL-XL to induce cell death.,Most potent BCL-XL inhibitor among tested compounds.
2019,https://doi.org/10.1038/s41418-019-0391-9,MCL-1 inhibitor,MCL-1,A-1210477,Most potent BCL-XL inhibitor among tested compounds.,Induces cytochrome c release from MCL-1-dependent mitochondria.
2019,https://doi.org/10.1038/s41418-019-0391-9,MCL-1 inhibitor,MCL-1,S63845,Induces cytochrome c release from MCL-1-dependent mitochondria.,Effective in inducing cytochrome c release from MCL-1-dependent cells.
2019,https://doi.org/10.1038/s41418-019-0391-9,MCL-1 inhibitor,MCL-1,AMG176,Selectively inhibits MCL-1 to induce apoptosis.,Validated as a true BH3 mimetic with effective mitochondrial activity.
2019,https://doi.org/10.1038/s41418-019-0391-9,MCL-1 inhibitor,MCL-1,AZD5991,Inhibits MCL-1 to promote apoptosis.,Induces cytochrome c release from MCL-1-dependent mitochondria.
2019,https://doi.org/10.1016/j.cmet.2019.01.018,Acetyltransferase inhibitor,EP300 (E1A-Associated Protein p300),EP300 Inhibitors,Inhibition of acetyltransferase activity.,"Promotes autophagy through deacetylation of proteins like PI3K3 and BECN1, enhancing their interaction with pro-autophagic complexes."
2019,https://doi.org/10.1016/j.cmet.2019.01.018,Deacetylase activator,SIRT1 (Sirtuin 1),SIRT1 Activators,Activation of deacetylation processes,"Deacetylates proteins such as LC3, promoting autophagy initiation and enhancing cellular metabolism."
2019,https://doi.org/10.1016/j.cmet.2019.01.018,Kinase activator,AMPK (AMP-Activated Protein Kinase),AMPK Activators,Energy sensor that regulates cellular energy homeostasis.,"Induces autophagy and inhibits mTORC1, promoting longevity and metabolic health."
2019,https://doi.org/10.1016/j.cmet.2019.01.018,Deacetylase activator,SIRT2 (Sirtuin 2),SIRT2 Activators,Deacetylation of proteins involved in autophagy.,"Deacetylates ATG5, supporting autophagy induction."
2019,https://doi.org/10.1016/j.cmet.2019.01.018,Acetyltransferase inhibitor,KATs (Lysine Acetyltransferases),KAT Inhibitors,Inhibition of acetylation processes.,Induces autophagy by reducing acetylation levels of key proteins.
2019,https://doi.org/10.1016/j.cmet.2019.01.018,Metabolic enhancer,NAD+ (Nicotinamide Adenine Dinucleotide),"NAD+ Precursors (e.g., NMN, NR)",Essential cofactor in redox reactions and energy metabolism.,"Enhances SIRT1 activity, promoting deacetylation and autophagy."
2019,https://doi.org/10.3390/ijms20081963,Not Specified Explicitly,Neutrophil serine proteases,Kanamycin-based Compound (KanCbz):,"Acts as a potent inhibitor of these proteases, which are involved in inflammatory lung conditions.",Demonstrated effectiveness in attenuating inflammation mediated by proteases
2019,https://doi.org/10.3390/molecules24010206,Protease inhibitor,Caspase-3,Reduced Amides (ψ(CH2NH)),"inhibit the activity of caspase-3, an important protease involved in apoptosis (programmed cell death).","Upon irradiation, the reduced amide peptides can inhibit caspase-3 activity. However, they do not form a covalent bond with the target protease; instead, they act as non-covalent inhibitors after activation by light"
2019,https://doi.org/10.3390/molecules24010206,Protease inhibitor,Caspase-3,Triazolo Peptides,triazolo peptides are also designed to inhibit caspase-3 activity.,The triazolo mimetics are more conformationally restricted compared to the reduced amides
2019,https://doi.org/10.1093/rb/rbz027,Not Specified Explicitly,Vascular Endothelial Growth Factor (VEGF),KLT (KLTWQELYQLKYKGI),": The KLT peptide is designed to activate VEGF receptors, promoting angiogenesis, which is the formation of new blood vessels.","It has been shown to promote endothelial cell (EC) growth, migration, and tubulogenesis, which are critical processes in angiogenesis"
2019,https://doi.org/10.1002/adfm.202402521,Not Specified Explicitly,Apoptotic Cells,Phosphatidylserine-Incorporated Exosome Mimetics (PS-EMs),"PS serves as an ""eat-me"" signal that is recognized by macrophages, facilitating phagocytosis of apoptotic cells. This mimetic aims to exploit the immunosuppressive properties of PS to enhance therapeutic effects in osteoporotic conditions.","The PS-EMs are designed to enhance the affinity for osteoclast precursors, thereby promoting targeted delivery and potentially modulating bone resorption."
2019,https://doi.org/10.1002/adfm.202402521,Not Specified Explicitly,CXCR3 Receptor,CXCR3 Antagonist (AMG487),"The CXCR3 receptor is involved in the recruitment and differentiation of osteoclast precursors at bone resorption sites. By blocking this receptor, the antagonist aims to mitigate osteoclast activity and bone loss.","The PS-EMs loaded with AMG487 effectively protect against bone loss in an ovariectomized mouse model, demonstrating their potential as anti-resorptive therapies."
2019,https://doi.org/10.1186/s12885-019-6103-5,Smac mimetic,Smac,LCL161,"LCL161 acts as an inhibitor of IAP (Inhibitor of Apoptosis) proteins, particularly targeting XIAP (X-linked Inhibitor of Apoptosis Protein), cIAP1, and cIAP2.","It promotes cell death by relieving the inhibition of caspases (caspase-3, -7, and -9) that are normally blocked by XIAP. This leads to the activation of the apoptotic pathway, facilitating the death of cancer cells, particularly in the context of osteosarcoma when combined with TNFα"
2019,https://doi.org/10.1186/s12885-019-6103-5,smac mimetic,Smac,GDC-0152,"Similar to LCL161, GDC-0152 inhibits IAP proteins, including XIAP, cIAP1, and cIAP2, thereby promoting apoptosis in cancer cells","GDC-0152 has been shown to sensitize osteosarcoma cells to TNFα-induced cell death, particularly when TNFα is provided exogenously, as these cells do not produce it autocrinely"
2019,https://doi.org/10.1016/j.celrep.2020.108286,Not Specified Explicitly,BCL-2,Obatoclax,Acts as a BH3 mimetic to promote apoptosis in cancer cells.,Acts as a BH3 mimetic to promote apoptosis in cancer cells.
2019,https://doi.org/10.1016/j.celrep.2020.108286,Not Specified Explicitly,BMI1,PTC028,"Inhibits BMI1, leading to decreased self-renewal and induction of senescence in tumor cells.","It drives cancer cells into a senescent state, which can be beneficial in controlling tumor growth."
2019,https://doi.org/10.1111/jfbc.12539,Hypolipidemic peptide,regulatory proteins involved in cholesterol metabolism,Lactostatin (IIAEK),"It operates via a new regulatory pathway in the calcium-channel-related mitogen-activated protein kinase (MAPK) signaling pathway, which is crucial for cholesterol degradation.",It has cholesterol-lowering properties.
2019,https://doi.org/10.1111/jfbc.12539,Hypolipidemic peptide,bile acid binding proteins.,Soystatin (VAWWMY),"It inhibits the micellar solubility of cholesterol, thereby reducing cholesterol absorption in the gastrointestinal tract.",Demonstrates in vitro and in vivo cholesterol-lowering effects.
2019,https://doi.org/10.1111/jfbc.12539,Anti-inflammatory peptide,Apolipoprotein A-I,Apolipoprotein A-I mimetic peptides (KRES),"They interact with lipids, remove lipid peroxides (LOOH), and activate antioxidant enzymes associated with HDL.",They exhibit anti-inflammatory and anti-atherogenic properties.
2019,https://doi.org/10.1111/jfbc.12539,Hypolipidemic peptide,fatty acid synthase (FAS),b-Conglycinin-derived peptides KNPQLR,"They inhibit FAS, which is involved in lipid synthesis.",Show significant inhibitory activity against purified chicken FAS and correlate with reduced lipid accumulation in adipocytes.
2019,https://doi.org/10.1111/jfbc.12539,Hypolipidemic peptide,fatty acid synthase (FAS),b-Conglycinin-derived peptides EITPEKNPQLR,"They inhibit FAS, which is involved in lipid synthesis.",Show significant inhibitory activity against purified chicken FAS and correlate with reduced lipid accumulation in adipocytes.
2019,https://doi.org/10.1111/jfbc.12539,Hypolipidemic peptide,fatty acid synthase (FAS),b-Conglycinin-derived peptides RKQEEDEDEEQQRE,"They inhibit FAS, which is involved in lipid synthesis.",Show significant inhibitory activity against purified chicken FAS and correlate with reduced lipid accumulation in adipocytes.
2019,https://doi.org/10.1021/acs.bioconjchem.9b00259,Synthetic antibody-like peptide.,Yeast regulatory protein Gal80.,Synbody,"Exhibits a high affinity (5 nM) for Gal80, significantly enhancing binding compared to monomeric peptides. This synbody binds to two different faces of the protein, mimicking the behavior of natural antibodies.","Synbody functions as a high-affinity protein interaction inhibitor by mimicking discontinuous epitopes of target proteins, enabling selective binding to disrupt pathogenic protein-protein interactions (PPIs) or modulate signaling pathways."
2019,https://doi.org/10.1021/acs.bioconjchem.9b00259,Cell-adhesion peptide.,Integrin proteins,Integrin-binding Cyclic RGDfK Peptide,"Used to create multivalent presentations on DNA scaffolds, effectively inhibiting melanoma cells that overexpress integrins. The study found that a construct with 15 peptides maximized efficiency in binding, demonstrating the importance of spatial arrangement in enhancing activity.","The integrin-binding cyclic RGDfK peptide specifically targets αvβ3 integrin with high affinity, inhibiting integrin-mediated signaling pathways critical for angiogenesis, tumor growth, and metastasis"
2020,https://doi.org/10.3390/nu12113261,inhibitor of inflammatory responses,Annexin A1 (AnxA1),Ac2-26,"has anti-inflammatory and anti-wrinkle effects in human keratinocyte (HaCaT) and fibroblast (Detroit 551) cells,.",decreases the expression of pro-inflammatory chemokines and cytokines by
2020,https://doi.org/10.1016/j.bios.2020.112683,structure mimic,zearalenone,ZEA mimicking peptide,"used as a substitute for the actual toxin in a competitive upconversion-linked immunosorbent assay (ULISA), a method designed to detect ZEA.",peptide binds to antibodies in competition with ZEA from the food sample. Its excellent ability to mimic ZEA was confirmed using nuclear magnetic resonance (NMR) and surface plasmon resonance (SPR) analysis.
2020,https://doi.org/10.3390/cells9020406,Not Specified Explicitly,Smac,GDC-0152,"Inhibits IAPs, promoting apoptosis in cancer cells.",Demonstrated anti-cancer effects in preclinical studies.
2020,https://doi.org/10.3390/cells9020406,Not Specified Explicitly,Smac,CUDC-427 (GDC-0917),Targets IAPs to enhance the efficacy of chemotherapy.,Shown to sensitize cancer cells to treatment.
2020,https://doi.org/10.3390/cells9020406,Not Specified Explicitly,Smac,Debio 1143 (AT-406),"inhibits IAPs, facilitating apoptosis.",Exhibited potential in various cancer types.
2020,https://doi.org/10.3390/cells9020406,Not Specified Explicitly,Smac,LCL161,Disrupts IAP function to promote cell death.,Effective in preclinical cancer models.
2020,https://doi.org/10.3390/cells9020406,Not Specified Explicitly,Smac,BI 891065 (BI5),Higher selectivity towards cIAP1 and cIAP2 compared to XIAP.,Modest efficacy in bladder and breast cancer cell lines.
2020,https://doi.org/10.3390/cells9020406,Not Specified Explicitly,Smac,Birinapant (TL32711),Binds to IAPs to promote apoptosis.,Undergoing clinical trials for various cancers
2020,https://doi.org/10.3390/cells9020406,Not Specified Explicitly,Smac,APG-1387,Inhibits IAPs to induce cancer cell death.,Inhibits IAPs
2020,https://doi.org/10.3390/cells9020406,Not Specified Explicitly,Smac,HGS1029 (AEG40826),Targets IAPs to enhance apoptosis.,Targets IAPs
2020,https://doi.org/10.3390/ijms21197349,Antimicrobial peptide mimetic,Natural antimicrobial peptide from wasp venom,Protonectin,Exhibits antifungal and antibacterial activity.,"Membrane-active mode of action, effective against various pathogens."
2020,https://doi.org/10.3390/ijms21197349,Antimicrobial peptide mimetic,Natural peptide found in frog skin.,Temporin-SHf,Provides a chemical defense against pathogens.,Moderate antimicrobial activity against E. coli and S. aureus.
2020,https://doi.org/10.3390/ijms21197349,Antimicrobial peptide mimetic,Analogue of Temporin-SHf.,TetraF2W-RR,Enhanced antimicrobial properties.,Improved activity against MRSA and other bacteria.
2020,https://doi.org/10.3390/ijms21197349,Antimicrobial peptide mimetic,Upgraded versions of Temporin.,Verine-L,Targeting bacterial infections.,Enhanced antimicrobial activity against S. aureus and E. coli.
2020,https://doi.org/10.3390/ijms21197349,Antimicrobial peptide mimetic,Upgraded versions of Temporin.,Horine,Targeting bacterial infections.,Enhanced antimicrobial activity against S. aureus and E. coli.
2020,https://doi.org/10.3390/ijms21197349,Peptidomimetic oligomers,Host-defense peptides.,g-AApeptides,Mimics the action of natural AMPs.,"mimic the primary structure of natural peptides, projecting a similar number of side chains, which allows them to interact effectively with bacterial membranes. They fold into discrete secondary structures, such as helical and β-turn-like formations, which are crucial for their function"
2020,https://doi.org/10.3390/ijms21197349,Peptidomimetic oligomers,Cyclic peptide antibiotics.,Cyclic g-AApeptides,Antimicrobial action.,"disrupt bacterial membranes. Their unique structure allows them to adopt a globally amphipathic conformation, which is essential for interacting with and permeabilizing bacterial membranes"
2020,https://doi.org/10.2147/IJN.S253576,Not Specified Explicitly,Integrins,RGD (Arg-Gly-Asp) Mimetic Peptide,"Promotes cell attachment and survival, particularly for dental pulp stem cells (DPSCs).",Enhances the proliferation and differentiation of DPSCs by facilitating their adhesion to the extracellular matrix (ECM).
2020,https://doi.org/10.2147/IJN.S253576,Not Specified Explicitly,Vascular endothelial growth factor,VEGF (Vascular Endothelial Growth Factor) Mimetic Peptide,"Stimulates angiogenesis, which is crucial for providing a blood supply to the regenerating pulp tissue.","Increases the secretion of VEGF by DPSCs, promoting vascularization in the dental pulp complex."
2020,https://doi.org/10.1038/s41467-020-19224-8,Not Specified Explicitly,TEAD (Transcriptional Enhanced Associate Domain),Proteomimetic 7,"promotes the interaction between YAP (Yes-associated protein) and TEAD, leading to pro-proliferative effects and activation of cell cycle activity in RKO cells. It also stimulates the expression of TEAD target genes in human cardiomyocytes and induces YAP nuclear translocation in primary juvenile rat heart cells, which is essential for cardiomyocyte proliferation","This proteomimetic is designed to inhibit the interaction between TEAD and its co-repressor VGL4, which is crucial in the Hippo signaling pathway."
2020,https://doi.org/10.1038/s41467-020-19224-8,Not Specified Explicitly,VGL4 (a transcriptional co-repressor),VGL4-derived Proteomimetic,The proteomimetic stabilizes a two-helix arrangement derived from VGL4 to bind TEAD and inhibit its interaction with VGL4.,"It has been characterized using surface plasmon resonance (SPR) and X-ray crystallography, confirming its binding mode and effectiveness in modulating the Hippo pathway"
2020,https://doi.org/10.1038/s41598-020-63336-6,Therapeutic peptide,Connexin 43 (Cx43),Gap27,"Gap27 is designed to mimic the function of Cx43, which is crucial for intercellular communication in the heart. Cx43 plays a significant role in the conduction of electrical impulses between cardiomyocytes, which is essential for maintaining normal heart rhythm and function.","Gap27 has been shown to improve cardiac function and reduce arrhythmogenesis in heart failure models. Specifically, it decreases the progression of cardiac dysfunction, reduces the incidence and severity of arrhythmias, and mitigates cardiac hypertrophy and adverse remodeling in high-output heart failure conditions.The peptide works by potentially influencing the phosphorylation status of Cx43, particularly at the S368 site, which is associated with the lateralization of Cx43 in cardiomyocytes"
2020,https://doi.org/10.1073/pnas.2001563117,Neuroprotective peptide mimetic.,Vascular Endothelial Growth Factor D (VEGFD),FMP6 (ALALKEIDEEWQRKGI),"FMP6 is designed to preserve dendritic architecture in neurons, which is crucial for cognitive functions.",In vivo studies showed that FMP6 completely protected layer 2/3 neurons from structural damage caused by middle cerebral artery occlusion (MCAO). It also significantly reduced infarct volume and improved functional recovery in stroke models when delivered nasally post-injury
2020,https://doi.org/10.1073/pnas.2001563117,Neuroprotective peptide mimetic.,Vascular Endothelial Growth Factor D (VEGFD),FMP69 (ALTLKE(aib)DEEWQRKGI),"Similar to FMP6, FMP69 aims to maintain neuronal structural integrity and support cognitive abilities.","FMP69 also demonstrated protective effects against MCAO-induced damage, preserving dendritic structures and reducing brain damage when administered nasally after stroke"
2020,https://doi.org/10.1073/pnas.2001563117,Not Specified Explicitly,control peptide,Scrambled Control (scrFMP6 - KEWLQALGIKDERAEI),Used as a control to assess the efficacy of FMP6.,"The scrambled version showed no protective effects against stroke-induced damage, confirming the specificity of the active mimetics"
2020,https://doi.org/10.1063/5.0019054,Not Specified Explicitly,Ubiquitin,Ubiquitin Variant,Involved in protein degradation and regulation of various cellular processes.,"Contains D-Gln35 in place of L-Gln35, which may affect its interaction with other proteins."
2020,https://doi.org/10.1063/5.0019054,Not Specified Explicitly,GB1 (a protein domain from protein G),GB1 Variant with Aib and β 3 Residues,Stabilizes protein structure and facilitates binding interactions.,"Contains Aib24, β 3 Lys28, β 3 Lys31, and Aib35, which may enhance stability and folding."
2020,https://doi.org/10.1063/5.0019054,Not Specified Explicitly,GB1 (a protein domain from protein G),GB1 Variant with ACPC and β 3 Residues,Stabilizes protein structure and facilitates binding interactions.,"Contains Aib24, β 3 Lys28, β 3 Lys31, and Aib35, which may enhance stability and folding."
2021,https://doi.org/10.1038/s41467-021-23985-1,Amyloid inhibitor,mutant p53 protein in cancer cells.,ADH-6,targets and dissociates mutant p53 aggregates in human cancer cells.,"It restores p53's transcriptional activity, leading to cell cycle arrest and apoptosis"
2021,https://doi.org/10.1186/s13046-021-02157-5,Small molecule inhibitor.,"Bim, Bad, and Bid (pro-apoptotic BH3-only proteins)",ABT-737,"Disrupts the interaction between pro-apoptotic and anti-apoptotic Bcl-2 proteins,",promotes apoptosis in cancer cells.
2021,https://doi.org/10.1186/s13046-021-02157-5,Small molecule inhibitor.,Bim and Bad,Navitoclax (ABT-263),"Induces apoptosis by inhibiting Bcl-2, Bcl-xL, and Bcl-w",activation of BAX and BAK.
2021,https://doi.org/10.1186/s13046-021-02157-5,Engineered peptide.,Bcl-xL,DT2216,"Designed to degrade Bcl-xL, reducing its off-target effects",enhancing apoptosis in cancer cells.
2021,https://doi.org/10.1186/s13046-021-02157-5,nanostructured peptide,BIM (a pro-apoptotic BH3-only protein),BIM BH3-mimetic peptide amphiphile,Facilitates the uptake of the mimetic,trigger cell death in cancer cells like HeLa and MEF.
2021,https://doi.org/10.1186/s13046-021-02157-5,Macromolecular drug carrier.,Various pro-apoptotic proteins,ELPs (Elastin-like polypeptides),"Enhances solubility and delivery of therapeutics,",electively accumulating in tumors to promote apoptosis
2021,https://doi.org/10.3390/cells10030597,Therapeutic peptide,Apolipoprotein A-I (apoA-I),4F Peptide,Anti-atherogenic effects,Reduces atherosclerosis in animal models; exhibits anti-inflammatory and antioxidant properties.
2021,https://doi.org/10.3390/cells10030597,Therapeutic peptide,Apolipoprotein A-I (apoA-I),D-4F Peptide,Similar to 4F but with improved oral bioavailability.,Reduces atherosclerosis in animal models; exhibits anti-inflammatory and antioxidant properties.
2021,https://doi.org/10.3390/cells10030597,Therapeutic peptide,Apolipoprotein A-I (apoA-I),5A Peptide,"Cholesterol removal and anti-inflammatory effects.
",Shown to reduce atherosclerosis in animal models; currently in phase 1 clinical trials.
2021,https://doi.org/10.3390/cells10030597,Therapeutic peptide,Apolipoprotein A-I (apoA-I),ETC-642,Cholesterol removal and anti-inflammatory effects.,Atheroprotective in animal models.
2021,https://doi.org/10.3390/cells10030597,Therapeutic peptide,Apolipoprotein A-I (apoA-I),FAMP/i-FAMP-D1,Promotes cholesterol efflux.,Modified to increase plasma half-life; effective in promoting cellular cholesterol efflux.
2021,https://doi.org/10.3390/cells10030597,Therapeutic peptide,Apolipoprotein E (apoE),ApoE Mimetic Peptides,acilitates hepatic clearance of apoB-containing lipoproteins.,Designed to lower LDL cholesterol (LDL-C); potential to impact LDL particle fate.
2021,https://doi.org/10.1002/anie.202102082,Peptidomimetic inhibitor,β-catenin,Bicyclic b-Sheet Mimetics (A-b6),"Inhibits the interaction between β-catenin and transcription factors, thereby blocking Wnt signaling.",Demonstrated robust Wnt inhibition with an IC50 of 8 µM and high inhibitory activity at 50 µM (2% residual activity)
2021,https://doi.org/10.1002/anie.202102082,Peptidomimetic inhibitor,β-catenin,Linear Analog (12-l),"Similar target as A-b6 and 12, aimed at inhibiting β-catenin interactions.",Exhibited low affinity (Kd approx. 2 mM) and reduced signal intensity due to proteolytic degradation
2021,https://doi.org/10.1371/journal.pbio.3001295,G protein-coupled receptor (GPCR) signaling,Gq protein,Gq Mimetic Protein (mGsqi),simulate the interaction of the Gq protein with the CCK1R,"interacts with the CCK1R, stabilizing the receptor and allowing for detailed structural analysis through cryo-electron microscopy"
2021,https://doi.org/10.1371/journal.pbio.3001295,G protein-coupled receptor (GPCR) signaling,Gs protein,Gs Mimetic Protein,"represent the Gs protein's interaction with the CCK1R,","Gs αH5 displayed a conformation that arises from unwinding of the far carboxyl-terminal residues, which is crucial for understanding the receptor's promiscuity in G protein coupling"
2021,https://doi.org/10.3390/bioengineering8010005,Not Specified Explicitly,Collagen triple helix.,Homotrimeric Collagen mimetic peptides (CMPs),"These peptides self-assemble into stable triple helices, mimicking the structural integrity of natural collagen.","They exhibit thermal stability and can facilitate the formation of higher-order structures, which are essential for tissue engineering applications."
2021,https://doi.org/10.3390/bioengineering8010005,Not Specified Explicitly,natural collagen with diverse amino acid sequences.,Heterotrimeric CMPs,Designed to form more complex structures that resemble the natural collagen fibrils found in tissues.,These CMPs can enhance the mechanical properties of biomaterials and improve cell interactions.
2021,https://doi.org/10.3390/bioengineering8010005,Not Specified Explicitly,Collagen and its functional domains.,Recombinant CMPs,"These peptides are produced using recombinant DNA technology, allowing for precise control over their sequence and structure.",They provide insights into collagen's molecular interactions and can be tailored for specific biomedical applications.
2021,https://doi.org/10.3390/bioengineering8010005,Not Specified Explicitly,Collagen and other ECM components.,Synthetic ECM Mimics,These materials aim to replicate the nano-scale structure and function of collagen.,They can support cell growth and tissue regeneration by providing a suitable environment for cellular activities.
2021,https://doi.org/10.3390/molecules26102937,Anticancer agents,Heat Shock Protein 90 (Hsp90),Sansalvamide A (San A) Derivatives,Inhibition of protein folding and stabilization.,"maintain cytotoxicity while incorporating triazoles, oxazoles, and thiazoles as amide bond surrogates."
2021,https://doi.org/10.3390/molecules26102937,Not Specified Explicitly,Tumor-associated αvβ3-integrin receptors,GlycoRGD Peptide,Selective binding to integrin receptors involved in cell adhesion and migration.,"The amide bond is replaced by a triazole without losing biological activity, enhancing stability and bioavailability."
2021,https://doi.org/10.3390/molecules26102937,Antimetastatic agents,Fascin,Migrastatin Analogues,Inhibition of cell motility.,Triazole analogues of migrastatin showed significant effects in reducing migration capacity in MDA-MB-361 cell lines.
2021,https://doi.org/10.3390/molecules26102937,Neuroprotective agents,Amyloid-β (Aβ) peptides,Amyloid-β Peptide Mimics,Inhibition of amyloid aggregation associated with neurodegenerative diseases.,"Triazole moieties replace amino acids in the turn region, preventing aggregation through self-assembly."
2021,https://doi.org/10.3390/molecules26102937,Non-steroidal anti-inflammatory drugs (NSAIDs),targeting pain pathways,Phenacetin and Acetaminophen Derivatives,Analgesic and antipyretic effects.,Replacement of the amide bond with triazole enhances anti-inflammatory and analgesic properties while reducing toxicity.
2021,https://doi.org/10.1016/j.jconrel.2020.12.017,Not Specified Explicitly,Prostate-Specific Membrane Antigen (PSMA)-binding proteins.,Anti-PSMA Peptide Mimetics,"The anti-PSMA peptide, WQPDTAHHWATL, is designed to specifically bind to PSMA, which is overexpressed on the surface of prostate cancer cells.","Enhances the binding and uptake of EMs by PSMA-positive prostate cancer cells (e.g., LNCaP and C4-2B cell lines), leading to targeted delivery of therapeutic agents."
2021,https://doi.org/10.1016/j.jconrel.2020.12.017,Not Specified Explicitly,"Natural exosomal surface proteins like CD63, CD81, and CD9.",Exosomal Marker Proteins,"These markers are present on the surface of engineered EMs to mimic the natural properties of exosomes, aiding in the recognition and uptake by target cells.","Helps maintain the structural integrity of EMs and supports their cellular internalization, similar to how natural exosomes interact with target cells."
2021,https://doi.org/10.1016/j.jconrel.2020.12.017,Not Specified Explicitly,"Proteins expressed by U937 monoblastic cells, such as integrins or adhesion molecules found on monocytes.",Monocyte-Derived Proteins,"These proteins help in the targeting and adhesion of EMs to specific tissues or cells, leveraging the natural tropism of monocyte-derived exosomes.","Improves the targeting efficiency of EMs in the tumor microenvironment, enhancing interaction with prostate cancer cells."
2021,https://doi.org/10.3390/app11010335,Monovalent Smac mimetic,Smac/DIABLO,LCL161,"Inhibits IAPs, promoting apoptosis in cancer cells.",Induces caspase-dependent apoptosis and can also affect the non-canonical NF-kB signaling pathway.
2021,https://doi.org/10.3390/app11010335,Bivalent Smac mimetic,Smac/DIABLO,Birinapant (TL32711),"Targets IAPs, particularly cIAP1 and cIAP2, to induce apoptosis.",Demonstrated to induce apoptosis and has been studied for its effectiveness in various cancers.
2021,https://doi.org/10.3390/app11010335,Monovalent Smac mimetic,Smac/DIABLO,GDC-0152,"Acts as a pan-IAP inhibitor, affecting XIAP, cIAP1, and cIAP2.",Induces apoptosis and has shown potential in combination therapies to enhance anti-cancer effects.
2021,https://doi.org/10.3390/app11010335,Monovalent Smac mimetic,Smac/DIABLO,AT-406 (Debio1143),"Specifically targets cIAP1 and cIAP2, similar to birinapant.",Induces apoptosis and has been evaluated in clinical settings.
2021,https://doi.org/10.3390/app11010335,Monovalent Smac mimetic,Smac/DIABLO,GDC-0917 (CUDC-427),"Inhibits IAPs, promoting apoptosis.",Evaluated for its anti-cancer potency in preclinical studies.
2021,https://doi.org/10.3390/app11010335,Bivalent Smac mimetic,Smac/DIABLO,BV6,A bivalent compound that inhibits IAPs.,Shown to suppress cancer cell progression and induce apoptosis in combination therapies.
2021,https://doi.org/10.1021/acs.analchem.1c02109,Not Specified Explicitly,Mycophenolic Acid (MPA),A2 (cyclic peptide mimetic),"The A2 peptide mimetic is designed to bind to the same antibody paratope as MPA, allowing it to compete with the actual drug in immunoassays. This mimetic is crucial for the development of sensitive detection methods for MPA in clinical samples.",The A2 mimetic demonstrated high selectivity for the recombinant MPA antibody fragment and was effective in competitive phage-based ELISA assays. It was further characterized by its ability to recognize the anti-MPA antibody and compete with free MPA at nanomolar levels
2021,https://doi.org/10.3390/antiox10020292,Not Specified Explicitly,PTP1B,(+)-trans-decursidinol,"Acts as a competitive inhibitor of PTP1B, which is involved in insulin signaling","Exhibits five hydrogen-bonding interactions with key residues (Gly183, Arg221, Gly220, Ile219, and Ala217) in the active site, stabilizing the enzyme and enhancing its inhibition"
2021,https://doi.org/10.3390/antiox10020292,Not Specified Explicitly,PTP1B,Pd-C-I,Functions as a mixed-type inhibitor of PTP1B.,"Forms hydrogen bonds with critical residues, contributing to its inhibitory effect on the enzyme ["
2021,https://doi.org/10.3390/antiox10020292,Not Specified Explicitly,PTP1B,Pd-C-II,Also acts as a mixed-type inhibitor of PTP1B.,"Similar to Pd-C-I, it interacts with essential residues, enhancing its binding and inhibition of the enzyme"
2021,https://doi.org/10.3390/antiox10020292,Not Specified Explicitly,PTP1B,Pd-C-III,Displays mixed-type inhibition of PTP1B.,"Engages with the enzyme's active site, although it has a different interaction profile compared to the other coumarins"
2021,https://doi.org/10.3390/antiox10020292,Not Specified Explicitly,α-glucosidase,α-Glucosidase Inhibition,"The coumarins also inhibit α-glucosidase, an enzyme that breaks down carbohydrates.","(+)-trans-decursidinol shows competitive inhibition, while Pd-C-I and Pd-C-II exhibit mixed-type inhibition, and Pd-C-III shows non-competitive inhibition"
2022,https://doi.org/10.3389/fphar.2022.864509,Small Peptide Mimetic,BMP-7,THR-184,Agonist of BMP signaling; antagonist of TGF-β signaling; regulates multiple signaling pathways involved in cellular injury,"Inhibits inflammation, apoptosis, fibrosis, and reverses epithelial to mesenchymal transition (EMT); controls Acute Kidney Injury (AKI)"
2022,https://doi.org/10.3389/fphar.2022.864509,Small Peptide Mimetic,MBMP-7,THR-123,Reverses established kidney fibrosis; induces nongenetic conversion of pancreatic exocrine cells to insulin-expressing cells,Successfully reversed kidney fibrosis in mouse models; demonstrated rapid reversal of diabetes in vivo
2022,https://doi.org/10.3389/fphar.2022.864509,Not Specified Explicitly,Bone Morphogenetic Protein 7,THR-184,Acts as a promoter for BMP signaling pathway and an inhibitor of TGFβ signaling  Pathway respectively,"Binds to BMP type I receptors, initiating BMP signaling cascade"
2022,https://doi.org/10.1016/j.addr.2021.114044,Not Specified Explicitly,Cytochrome c,Cyt c 86-101,Mimics the function of Cytochrome c.,involved in apoptosis signaling.
2022,https://doi.org/10.1016/j.addr.2021.114044,Not Specified Explicitly,Cytochrome c,Cyt c 77-101,Mimics the function of Cytochrome c.,involved in apoptosis.
2022,https://doi.org/10.1016/j.addr.2021.114044,Not Specified Explicitly,Tumor suppressor protein p14ARF,ARF 1-22,Binds to HDM2.,"Inhibits HDM2, potentially restoring p53 function."
2022,https://doi.org/10.1016/j.addr.2021.114044,Not Specified Explicitly,Protein C inhibitor (PCI),SERPINA5,Inhibits serine proteases.,Regulates coagulation and inflammation.
2022,https://doi.org/10.1016/j.addr.2021.114044,Not Specified Explicitly,Histone H3,Cyclic CPP from Histone H3 Tail,Mimics histone interactions.,involved in gene regulation.
2022,https://doi.org/10.1016/j.addr.2021.114044,Not Specified Explicitly,p53 epitope,Helix-loop-helix cyclic peptide,Inhibits p53/HDM2 interaction.,Reactivates p53 functionality.
2022,https://doi.org/10.1016/j.addr.2021.114044,Not Specified Explicitly,Amyloid peptide from VEGFR2,Vascin,Enters cancer cells and binds to p53.,Restores p53 functionality.
2022,https://doi.org/10.1016/j.addr.2021.114044,Not Specified Explicitly,Intrinsically disordered region of p53,LinkTer peptide,Modulates p53 activity.,Inhibits interactions that lead to p53 degradation.
2022,https://doi.org/10.1016/j.addr.2021.114044,Not Specified Explicitly,Estrogen receptor,R4K1,Binds to estrogen receptor.,"High affinity for estrogen receptor, potentially modulating its activity."
2022,https://doi.org/10.1016/j.addr.2021.114044,Not Specified Explicitly,PCNA (proliferating cell nuclear antigen),APIM,Interacts with PCNA.,Modulates DNA replication and repair processes.
2022,https://doi.org/10.1016/j.addr.2021.114044,Not Specified Explicitly,NEMO/IKKb interaction,Bicyclic peptides,Inhibits NEMO/IKKb interaction.,Affects NF-kB signaling pathway.
2022,https://doi.org/10.1016/j.addr.2021.114044,Not Specified Explicitly,BCL9 protein,Heptapeptides,Mimics the α-helical domain of BCL9.,Inhibits β-catenin interaction.
2022,https://doi.org/10.1016/j.addr.2021.114044,Not Specified Explicitly,Host defense peptide,cTI (tachyplesin-I),Antimicrobial activity.,Induces apoptosis in cancer cells.
2022,https://doi.org/10.1016/j.addr.2021.114044,Not Specified Explicitly,CK2a/CK2b interaction,CK2b-mimicking cyclic peptides,Modifies CK2a/CK2b interaction.,Affects cell signaling pathways.
2022,https://doi.org/10.1016/j.addr.2021.114044,Not Specified Explicitly,PKB substrate motif,FCHO1 560-571,Interacts with PKB.,Modulates signaling pathways related to cell growth.
2022,https://doi.org/10.1016/j.addr.2021.114044,Not Specified Explicitly,PP2A and SET interaction,PP2A and SET interaction,Blocks oncogenic interactions.,Reduces tumor growth.
2022,https://doi.org/10.1016/j.addr.2021.114044,Tumor suppressor mimetic.,p53,p53-derived peptides,Inhibits MDM2 interaction.,"Reactivates p53, promoting apoptosis in cancer cells."
2022,https://doi.org/10.1016/j.addr.2021.114044,Oncogene inhibitor.,MDM2,MDM2 inhibitors,Inhibits p53 degradation.,"Restores p53 activity, leading to tumor suppression."
2022,https://doi.org/10.1016/j.addr.2021.114044,Oncogene mimetic.,BCL9,BCL9-derived peptides,Inhibits β-catenin interaction.,"Modulates Wnt signaling pathway, affecting cell proliferation."
2022,https://doi.org/10.1016/j.addr.2021.114044,Angiogenesis inhibitor.,Vascular Endothelial Growth Factor (VEGF),VEGF-derived peptides,Inhibits angiogenesis.,"Reduces tumor blood supply, limiting growth."
2022,https://doi.org/10.1016/j.addr.2021.114044,Oncogene inhibitor.,c-Myc,c-Myc inhibitors,Disrupts c-Myc/Max dimerization.,Inhibits transcription of target genes involved in cell growth.
2022,https://doi.org/10.1016/j.addr.2021.114044,Apoptosis-inducing mimetic.,Fas Ligand (FasL),FasL-derived peptides,Induces apoptosis.,Triggers cell death in cancer cells.
2022,https://doi.org/10.1016/j.addr.2021.114044,Immunomodulatory mimetic.,Interleukin-2 (IL-2),IL-2-derived peptides,Enhances T-cell activation.,Boosts immune response against tumors.
2022,https://doi.org/10.1016/j.addr.2021.114044,Tumor suppressor mimetic.,TGF-β inhibitors,Transforming Growth Factor Beta (TGF-β),Inhibits TGF-β signaling.,Reduces tumor progression and metastasis.
2022,https://doi.org/10.1016/j.addr.2021.114044,Cell adhesion mimetic.,Integrins,Integrin-derived peptides,Modulates cell adhesion.,Affects tumor cell migration and invasion.
2022,https://doi.org/10.1016/j.addr.2021.114044,Chemokine receptor inhibitor.,CXCR4,CXCR4 antagonists,Inhibits chemokine signaling.,Reduces metastasis and tumor growth.
2022,https://doi.org/10.1016/j.addr.2021.114044,Not Specified Explicitly,L2,Human Papillomavirus Minor Capsid Protein L2,Involved in viral entry into host cells.,Facilitates infection.
2022,https://doi.org/10.1021/acscentsci.1c01293,Not Specified Explicitly,Heparan sulfate (HS),Pixatimod (PG545),"Acts as a coreceptor for the SARS-CoV-2 spike protein, facilitating viral entry into host cells by interacting with the ACE2 receptor.
Disrupts the interaction between the spike protein and ACE2, thereby inhibiting viral infection.","Pixatimod binds to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, destabilizing it and preventing its binding to ACE2.
Demonstrated potent inhibition of SARS-CoV-2 infection in various cell types, including monkey Vero E6 cells and human bronchial epithelial cells, at therapeutically safe concentrations.
Retains effectiveness against multiple variants of concern (VOC) such as Alpha, Beta, Delta, and Omicron, indicating broad antiviral activity."
2022,https://doi.org/10.1021/acscentsci.1c01293,Cytokine mimetic,Interleukin-2 (IL-2) and Interleukin-15 (IL-15),Neo-2/15,"Potently activates and expands cytotoxic CD8+ T cells and NK cells, supporting antitumor immunity with reduced toxicity","Mimics IL-2 and IL-15 signaling by selectively binding IL-2Rβγc, driving immune cell activation without engaging CD25, thus minimizing side effects"
2022,https://doi.org/10.3389/fphar.2022.864509,Not Specified Explicitly,BMP-7,THR-184,Acts as an agonist of BMP signaling and a potent antagonist of TGFβ signaling.,"Inhibits inflammation, apoptosis, and fibrosis; reverses epithelial to mesenchymal transition (EMT); controls Acute Kidney Injury (AKI)."
2022,https://doi.org/10.3389/fphar.2022.864509,Not Specified Explicitly,BMP-7,THR-123,Agonist that signals through the activin-like kinase three receptor (ALK3).,"Initiates phosphorylation of Smads 1, 5, and 8; blocks apoptosis; suppresses renal tubule cell inflammation; does not induce ectopic bone formation."
2022,https://doi.org/10.3389/fphar.2022.864509,Not Specified Explicitly,BMP-9,P3,Enhances BMP-9-induced Smad1/5 phosphorylation selectively in human pulmonary artery endothelial cells.,Inhibits BMP-4-induced Smad1/5 phosphorylation in human dermal microvascular endothelial cells.
2022,https://doi.org/10.3389/fphar.2022.864509,Not Specified Explicitly,BMP-7,BFP-1/2/3,Induces alkaline phosphatase activity in multipotent bone marrow stromal cells (MBSCs).,Promotes osteogenic differentiation.
2023,https://doi.org/10.1021/acs.jmedchem.3c01412,Not Specified Explicitly,p53,Sulfono-γ-AApeptides,Blocking the interaction of p53 with its negative regulators MDM2 or MDMX.,"This  restores p53’s tumor-suppressing activity, potentially leading to cancer cell apoptosis."
2023,https://doi.org/10.1021/acs.jmedchem.3c01412,Not Specified Explicitly,GLP-1,Sulfono-γ-AApeptides,treatment of type 2 diabetes.,"Mimicry of GLP-1, which is involved in glucose regulation by stimulating insulin secretion."
2023,https://doi.org/10.1021/acs.jmedchem.3c01412,Apoptogenic cell-penetrating peptides (CPPs),Cyt c,Cyt c86–101 and Cyt c77–101,clinical utility in cancer therapy.,Induce tumor cell apoptosis by mimicking cytochrome c's role in activating the intrinsic apoptotic pathway.
2023,https://doi.org/10.1021/acs.jmedchem.3c01412,Peptide mimetic,p14ARF,ARF1-22,restricts the proliferation of different cancer cells by mimicking the p14ARF protein,Regulates GAP-mediated GTP hydrolysis (via N-terminal residues and myristoylation)
2023,https://doi.org/10.1016/j.cej.2023.144594,Not Specified Explicitly,Aspartate-rich peptides,Asp8 Peptide Mimetics,designed to mimic the bone-targeting properties of proteins that naturally interact with bone tissue.,"The Asp8 peptide binds preferentially to hydroxyapatite in bone, thereby directing the engineered exosome-mimetics to bone tissues."
2023,https://doi.org/10.1016/j.cej.2023.144594,Not Specified Explicitly,"Mimics aspects of proteins involved in RNA transport and delivery, though it primarily functions as an RNA carrier.",miR-26a Carrier Mimetics,"While not a protein itself, the EMs are designed to mimic proteins involved in RNA transport for targeted gene delivery. miR-26a regulates the expression of proteins such as GSK-3β.","By delivering miR-26a, the EMs modulate the Wnt signaling pathway through the inhibition of GSK-3β, leading to β-catenin accumulation and enhanced osteogenesis."
2023,https://doi.org/10.1016/j.bioactmat.2022.05.029,Angiogenic peptide,Vascular Endothelial Growth Factor (VEGF),VEGF-mimetic Peptide (QK),"Promotes attachment and proliferation of endothelial cells, and induces angiogenesis.","Activates VEGF receptors, similar bioactivity to VEGF, enhances vascular development, and induces capillary network formation."
2023,https://doi.org/10.1016/j.bioactmat.2022.05.029,Not Specified Explicitly,Vascular Endothelial Growth Factor (VEGF),TAMRA-labeled VEGF-mimetic Peptide,Used for tracking and validating the thiol-ene reaction on scaffolds.,Allows for monitoring of peptide conjugation and interaction with scaffolds.
2023,https://doi.org/10.1016/j.bioactmat.2022.05.029,Cell adhesion peptide,Integrin-binding sites found in various extracellular matrix proteins.,RGD-FITC Peptide,Promotes cell adhesion and migration.,Used to validate the thiol-ene reaction on the fibrous scaffolds.
2023,https://doi.org/10.1016/j.jtos.2023.12.002,Therapeutic peptide mimetic.,Pigment Epithelium-Derived Factor (PEDF),PEDF Peptide Mimetic (Ppx),"Promotes cell survival, has neuroprotective and anti-inflammatory properties.","Alleviates dry eye symptoms, restores corneal sensitivity and tear secretion, improves endothelial barrier function."
2023,https://doi.org/10.1101/2023.10.30.564794,Not Specified Explicitly,Antimicrobial peptides (AMPs).,TM5,Kills Pseudomonas aeruginosa by disrupting bacterial membranes.,"Exhibits rapid bactericidal activity, effectively killing P. aeruginosa within 30-60 minutes in vitro. Reduces bacterial load in the lungs of infected mice within 24 hours in vivo."